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I. Summary 
 
Anti-infective agents targeting the bacterial translation machinery must differentiate between 
prokaryotic and eukaryotic ribosomes. This discrimination provides the basis for the selectivity 
and toxicity of ribosomal drugs. Despite the use of ribosomal drugs for decades, we still do only in 
part understand the principles governing selectivity and toxicity of these agents.  
Most antibiotics that bind to the ribosome have been shown to interact directly with the ribosomal 
RNA (rRNA). rRNA is involved in all essential steps of translation e.g. selection of cognate 
aminoacyl-tRNA, peptide bond formation. The site of codon-anticodon interaction is located in the 
small ribosomal subunit and termed “decoding region” or A (aminoacyl)-site. It is mainly 
composed of small-subunit rRNA, i.e., helix 44 of bacterial 16S rRNA. The decoding region is 
also the binding site for the 2-deoxystreptamine aminoglycosides. Recent advances in X-ray 
crystallography have greatly contributed to the understanding of the structural interactions 
between aminoglycosides and the ribosomal decoding A-site.  
Aminoglycosides are polycationic amino sugars which are composed of a common core, termed 
neamine, in which a glycopyranosyl ring (ring I) is attached to position 4 of a 2-deoxystreptamine 
ring (ring II). Toxicity of 2-deoxystreptamines, i.e., ototoxicity and nephrotoxicity, limits their 
clinical use. The toxicity of aminoglycosides has been attributed in part to inhibition of 
mitochondrial protein synthesis. A single nucleotide polymorphism between bacterial 16S rRNA 
and its eukaryotic cytoplasmic counterpart, i.e., corresponding 16S rRNA position 1408A versus 
G (an adenine is found in prokaryotic ribosomes versus a guanine in eukaryotic cytoribosomes), 
has been suggested to form the basis for the selectivity of aminoglycoside antibiotics. The 
mitochondrial rRNA carries a susceptible adenine at the corresponding position providing a 
molecular explanation for the toxicity of these drugs. Toxicity of aminoglycosides seems also to 
be associated with genetic alterations of the human mitochondrial rRNA.  
Investigation of rRNA structure-function relationships in most organisms is complicated by the 
presence of a multitude of chromosomal rrn genes encoding rRNA. The multiplicity of genes 
encoding cytoplasmic and mitochondrial rRNA in higher eukaryotes does not allow for genetic 
manipulation of genes encoding ribosomal nucleic acids. Likewise, most bacterial species carry 
multiple rrn operons in the chromosome. The presence of several operons hampers the isolation 
of rrn mutants due to a recessive phenotype. In addition, a mixture of wild-type and mutated 
ribosomes complicates biochemical investigations. These limitations in investigating structure-
function relationships of bacterial ribosomal nucleic acids at a genetic level were in part met by 
generating Mycobacterium smegmatis ΔrrnB, the first eubacterial organism carrying a single 
functional rrn operon which is amenable to genetic manipulations. Mutant ribosomal RNA 
operons were introduced into M. smegmatis ΔrrnB resulting in bacterial/eukaryotic hybrid 
ribosomes. 
 
  II 
1) Hybrid ribosomes carrying the rRNA decoding A-site of higher eukaryotic cytoribosomes show 
pronounced resistance to aminoglycoside antibiotics, equivalent to that of rabbit reticulocyte 
ribosomes. This finding suggests that helix 44 of the rRNA decoding A-site behaves as an 
autonomous domain, which can be exchanged between ribosomes of different phylogenetic 
domains for study of function. 
2) Compared to hybrid ribosomes with the A-site of human cytosolic ribosomes, aminoglycoside 
susceptibility of hybrid ribosomes with the A-site of human mitochondrial ribosomes was found to 
be variable and to correlate with the relative cochleotoxicity of these drugs. This result provides 
experimental support for aminoglycoside-induced dysfunction of mitochondrial protein synthesis. 
3) Recent reports on an interplay of S12 on 16S rRNA function and susceptibility to 2-
deoxystreptamine aminoglycosides prompted us to study the role, if any, between rpsL K42R and 
alterations in 16S-rRNA helix 44 in more detail. We find that the non-restrictive rpsL K42R 
mutation does not affect the 2-deoxystreptamine susceptibility of various rRNA mutations in H44.  
The data presented in this thesis demonstrate that the model system developed properly reflects 
the situation in eukaryotic ribosomes and is useful to study the interaction of aminoglycoside 
antibiotics with eukaryotic ribosomes. With this, we can identify residues critical for the selectivity 
of aminoglycosides. Ultimately, a detailed understanding of the structure-function relationships 
will lead to the improvement of existing antimicrobials and the rational design of effective novel 
compounds. 
 
 
 
 
 
 
 
III 
II. Zusammenfassung 
 
Antiinfektiöse Substanzen, welche an der bakteriellen Translationsmaschinerie angreifen, 
müssen zwischen prokaryontischen und eukaryontischen Ribosomen unterscheiden. Eine solche 
Unterscheidung ist die Grundlage für die Selektivität und Toxizität von Antibiotika. Obwohl 
derartige Antibiotika seit Jahrzehnten eingesetzt werden, sind die Prinzipien, welche Selektivität 
und Toxizität dieser Substanzen bestimmen, noch immer nur teilweise verstanden. 
Für die meisten Antibiotika, die am Ribosom angreifen, wurde gezeigt, dass sie direkt mit der 
ribosomalen RNA (rRNA) interagieren. Die rRNA ist an allen wesentlichen Schritten der 
Translation beteiligt, z. B. an der Auswahl passender Aminoacyl-tRNA und der Bildung von 
Peptidbindungen. Der Ort der Codon-Anticodon-Wechselwirkung befindet sich in der kleinen 
ribosomalen Untereinheit und wird als „Decodierungsregion“ oder A-Stelle (Aminoacylstelle) 
bezeichnet. Er besteht hauptsächlich aus rRNA der kleinen Untereinheit, d. h. Helix 44 der 
bakteriellen 16S-rRNA. Die Decodierungsregion ist auch die Bindestelle für 2-Desoxystreptamin-
Aminoglykoside. 
Aminoglykoside sind polykationische Aminozucker, die aus einem gemeinsamen Grundgerüst, 
dem Neamin, bestehen, in dem ein Glycopyranosylring (Ring I) an Position 4 eines 2-
Desoxystreptaminrings (Ring II) gebunden ist. Die Toxizität von 2-Desoxystreptaminen, - und hier 
besonders die Ototoxizität -, schränkt ihre klinische Anwendung stark ein. Die Toxizität von 
Aminoglykosiden wird zum Teil auf eine Hemmung der mitochondrialen Proteinsynthese 
zurückgeführt. Hierbei wird postuliert, dass ein einzelner Nukleotidpolymorphismus zwischen der 
bakteriellen 16S-rRNA und ihrem eukaryontischen zytoplasmatischen Pendant an Position 1408 
(ein Adenin findet man in prokaryontischen Ribosomen, ein Guanin dagegen in eukaryontischen 
Zytoribosomen) für die Selektivität von Aminoglykosidantibiotika verantwortlich ist. 
Demgegenüber enthält die mitochondriale rRNA an der entsprechenden Position ein Adenin, was 
eine mögliche molekulare Erklärung für die Toxizität dieser Arzneimittel liefert. Darüber hinaus 
scheint ein Zusammenhang zwischen der Toxizität von Aminoglykosiden und gewissen 
genetischen Veränderungen der humanen mitochondrialen rRNA zu bestehen.  
Die Vielzahl von Genen, welche für zytoplasmatische und mitochondriale rRNA in höheren 
Eukaryonten kodieren, macht ihre genetische Manipulation praktisch unmöglich. Auch die 
meisten Bakterienarten tragen mehrere rrn-Operons auf dem Chromosom. Die Gegenwart 
mehrerer Operons erschwert die Isolation von rrn-Mutanten aufgrund eines rezessiven 
Phänotyps. Darüber hinaus erschwert eine Mischung aus Wildtyp- und mutierten Ribosomen 
biochemische Untersuchungen. Diese Einschränkungen bei der Untersuchung von Struktur-
Funktionsbeziehungen von bakteriellen ribosomalen Nukleinsäuren auf genetischer Ebene 
werden durch Mycobacterium smegmatis ΔrrnB umgangen. M. smegmatis ΔrrnB ist der erste 
eubakterielle Organismus, der ein einziges funktionelles rrn-Operon trägt, das für genetische 
Manipulationen zugänglich ist.  
IV 
1) Hybridribosomen, welche die rRNA-Decodierungsstelle (A-Stelle) der Zytoribosomen höherer 
Eukaryonten aufweisen, zeigen eine ausgeprägte Resistenz gegenüber Aminoglykosidantibiotika 
– gleichwertig mit der von Ribosomen aus Kaninchenretikulozyten. Dieses Ergebnis weist darauf 
hin, dass Helix 44 der rRNA-Decodierungsstelle (A-Stelle) sich als eine autonome Domäne 
verhält, die zur Funktionsanalyse zwischen Ribosomen verschiedenen phylogenetischen 
Ursprungs ausgetauscht werden kann. 
2) Im Vergleich zu Hybridribosomen mit der A-Stelle humaner zytosolischer Ribosomen zeigen 
Hybridribosomen mit der A-Stelle humaner mitochondrialer Ribosomen unterschiedliche 
Aminoglykosid-Empfindlichkeit, welche mit der relativen Cochleotoxizität dieser Substanzen 
korreliert. Dieses Ergebnis liefert experimentelle Hinweise auf eine Aminoglykosid-induzierte 
Fehlfunktion der mitochondrialen Proteinsynthese. 
3) Neuere Berichte über ein Zusammenspiel des ribosomalen Proteins S12 und der 16S-rRNA im 
Hinblick auf die Empfindlichkeit gegenüber 2-Desoxystreptamin-Aminoglykosiden veranlassten 
uns zu untersuchen, ob eine Funktionsbeziehung zwischen rpsL K42R und Veränderungen in der 
Helix 44 der 16S-rRNA besteht. Dabei konnten wir zeigen, dass die nichtrestriktive rpsL-K42R-
Mutation die 2-Desoxystreptamin-Empfindlichkeit verschiedener rRNA-Mutationen in H44 nicht 
beeinflusst. 
Die in dieser Dissertation erbrachten Daten zeigen, dass das entwickelte Modellsystem die 
Situation in eukaryontischen Ribosomen korrekt widerspiegelt und zur Untersuchung der 
Wechselwirkung von Aminoglykosidantibiotika mit eukaryontischen Ribosomen geeignet ist. Auf 
diese Weise können für die Selektivität von Aminoglykosiden entscheidende Strukturen 
identifiziert werden. Letztlich ist ein genaues Verständnis der Struktur-Funktionsbeziehungen 
entscheidend zur Verbesserung bestehender antimikrobieller Substanzen wie auch zur rationalen 
Entwicklung neuartiger Verbindungen. 
1. Introduction 
 
1.1 Mechanisms of Translation 
 
Decades of genetic, biochemical, and biophysical characterization have established our current 
understanding of translation as a complex, multistep, and multicomponent process that requires 
intricate communication to achieve high levels of speed, accuracy, and regulation. Translation 
converts genetic information into proteins that execute the myriad tasks necessary for life. It is 
estimated that, in the simplest prokaryotic organisms, nearly half the dry weight of the cell and 
more than 80% of its energy are used to drive the synthesis of proteins. 
 
Protein synthesis can be divided into four distinct phases: initiation, elongation, termination and 
recycling (Fig. 1). Each stage requires the coordination of multiple components of the 
translational machinery and the precise timing of molecular events. The role of the initiation 
phase is to position the ribosome correctly on the mRNA so that protein synthesis initiates at the 
right place in the correct reading frame. The result is a 70S ribosome programmed with the start 
codon of the mRNA and the initiator-tRNA located at the P-site of the ribosome, a so-called 70S 
initiation complex. In principle, there are three binding sites for the tRNA on the ribosome. The A-
site binding aminoacylated t-RNA, the P-site holding peptidyl t-RNA, and the E-site as exit site for 
hydrolyzed t-RNA. The elongation phase involves the movement of tRNAs in a cyclic fashion 
through the three tRNA binding sites A → P → E, where the number of cycles is dictated by the 
length of the polypeptide being synthesized. The first step in the cycle involves binding of the aa-
tRNA to the A-site, which is facilitated by a protein factor EF-Tu. EF-Tu hydrolyzes GTP and 
dissociates from the ribosome, allowing the A-tRNA to accommodate on the large subunit (Fig. 
1). Peptide-bond formation proceeds, transferring the entire polypeptide chain from the peptidyl-
tRNA in the P-site to the aminoacyl moiety of the tRNA A-site. Now the ribosome has a peptidyl-
tRNA at the A-site and a deacylated-tRNA at the P-site. This ribosomal state is highly dynamic 
and the tRNAs move back and forth into so-called A/P (A/P denotes that the tRNA is in the A-site 
on the 30S and P-site on the 50S) and P/E (P/E denotes that the tRNA is in the P-site on the 30S 
and E-site on the 50S) hybrid states. Next, translocation of the tRNAs occurs, a process that is 
catalyzed by a second elongation factor, EF-G. Binding of EF-G to the ribosome locks the tRNAs 
in hybrid states and the subsequent translocation reaction shifts the peptidyl-tRNA from the A/P 
hybrid state to the P-site and the deacylated tRNA from the P/E to the E-site – the outcome being 
that the A-site is free to bind the next incoming aa-tRNA. When a stop signal in the mRNA enters 
the A-site, the ribosome is then channeled into termination and recycling phases. The stop 
signals are recognized by protein termination factors, RF1 and RF2, which function to hydrolyze 
the peptidyl-tRNA bond and release the translated polypeptide chain from the ribosome. RF1 and 
RF2 are recycled from the ribosome by a third release factor RF3, in a GTP-dependent fashion. 
The post-termination ribosome complexes are then split into subunits by the concerted action of 
1
EF-G and the ribosome recycling factor RRF and the components recycled for the next round of 
translation (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  The prokaryotic translation cycle. Shown is the current model, which has been 
derived from biochemical and biophysical studies. Initiation, mediated by initiation factors 1,2, 
and 3 (green-shaded circles), culminates in the joining of 30S (gray) and 50S (purple) subunits 
on the mRNA message primed with initiator tRNA (gray line with red circle) in the P site. This 
complex, aided by the elongation factors Tu and G (blue-shaded circles), subsequently 
undergoes multiple rounds of elongation. Termination, under the control of release factors 1, 2 
and 3 (red-shaded circles), frees the newly synthesized polypeptide upon recognition of the 
stop codon. Ribosomal recycling factor (yellow circle) and elongation factor G then prepare the 
translational machinery for subsequent initiation events. Abbreviations: A, ribosomal 
aminoacyl-tRNA site; P, ribosomal peptidyl-tRNA site; E, ribosomal exit site; G, elongation 
factor G; RRF, ribosome recycling factor; Tu, elongation factor Tu. Figure taken from reference 
(29).   
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1.2 Ribosome: composition and structure  
 
The central component in translation is the ribosome, a massive (megadaltons), multisubunit 
biomolecular machine. The ribosome is approximately globular, its average diameter ranging 
from 2.5nm (Escherichia coli) to 2.8nm (mammalian). Mammalian ribosomes exist in two forms: 
cytoplasmic ribosomes and mitochondrial ribosomes (mitoribosomes). The sizes and molecular 
weights of ribosomes from three domains of life are listed in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Ribosome components from the three domains of life. Table taken from reference (41). 
 
Ribosomes are made up of two subunits, both of which consist of ribosomal RNA (rRNA) and 
many specific ribosomal proteins (r-proteins). Ribosomes translate genetic information stored on 
the messenger RNA (mRNA) into polypeptides. Figure 2A shows the crystal structure of 70S 
ribosome with large (50S) and small (30S) ribosomal subunits from the thermophilic bacterium 
Thermus thermophilus. The small subunit contains the decoding site (Fig. 2B) where the mRNA 
sequence is read in blocks of three nucleotides, called codons. Each codon denotes one of 
twenty different amino acids, and each amino acid is ferried to the ribosome by its own transfer 
RNA (tRNA) or set of tRNAs. Every tRNA has an anticodon sequence that makes a specific 
match with the corresponding mRNA codon. The mRNA passes through two narrow channels on 
the 30S subunit to be displayed at the interface decoding site, where it interacts with the tRNA 
anticodon (10, 33, 44, 45). The basepairing match between the tRNA anticodon and mRNA 
codon is checked by the decoding site within the A site of the small subunit.  
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A 
 
B 
 
 
Figure 2. Crystal structure of the ribosome. (A) 70S ribosome complexed with mRNA and 
tRNA.(B) Exploded view of the 30S subunit in the 70S ribosome, showing the locations of  
A-(red), P-(green), and E-(gold) site tRNAs. Figure taken from reference (44). 
 
1.2.1 Small subunit ribosomal proteins  
 
The structural studies of the ribosome confirmed the predominance of rRNA at the ribosomal 
active sites, but also revealed that a number of r-proteins were located in positions of functional 
importance, for example, S12 at the decoding centre. Both proteins and rRNA are essential for 
optimal ribosome function. There are 21 r-proteins (S1–S21) in the small subunit of E. coli 
ribosomes and they are universally conserved through all three domains of life (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Concordance between the universally conserved ribosomal proteins in small subunit 
from the three kingdoms of life. Table taken from reference (58). 
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Binding of cognate tRNA to the A site induces a transition in the 30S subunit from the open to the 
closed form. This involves a rotation of the head and movement of body (see red arrows in Fig. 
7A) towards the decoding site. The closed form brings elements of S12 and 16S rRNA into 
contact. In particular, the interactions of G530, A1492, and A1493 with the codon-anticodon helix 
minor groove make the transition to the closed form favorable for cognate but not near-cognate 
tRNA. Binding of near-cognate tRNA to the ribosome indicates that it associates weakly with the 
A-site codon, the 30S remains in an open conformation, similar to when the decoding centre is 
unoccupied. 
 
Ribosomal protein (r-protein) S12 encoded by rpsL gene is a critical component of the decoding 
center of the 30S ribosomal subunit and involved in recognizing the codon-anticodon positions at 
the A-site. Mutations in the r-protein S12 are known to affect ribosomal accuracy to various 
extents, resulting in what is known as restrictive or non-restrictive rpsL mutations. Mutations in 
S12 that block salt-bridge formation between S12 and nucleotides of the 16S may destabilize the 
closed form and result in restrictive (hyperaccurate) ribosomes (9). The classical S12 mutations 
were isolated as streptomycin resistance mutants (5).  
 
Crystal structures of streptomycin bound to the small ribosomal subunit of T. thermophilus have 
revealed that the lysine residue 42 (E. coli numbering) of ribosomal protein S12 forms contact to 
the phosphate backbone of 16S-rRNA helix 27 (H27) via a salt bridge to the phosphate group of 
residue A913. K42 also forms two hydrogen bonds with streptomycin (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A model of three-dimensional crystal structure of T. thermophilus ribosomal 
decoding A-site with bound streptomycin (Protein Data Bank, 1FJG.pdb). Amino-acid residues 
of S12 are shown labelled according to atoms: carbon – green, nitrogen – blue, oxygen – red. 
H44 (pink), H27 (violet), streptomycin (light blue), Hydrogen bonds (black dotted lines) and salt 
bridge (red dotted line) are shown. 
5
 
A number of the mutations in the r-protein S12 that confer resistance to, and in some cases even 
dependence on streptomycin, map within a loop of S12 that directly contacts the drug molecule (Fig. 
7A) (26). Of these mutations, positions Lys42 and Lys87 directly interact with streptomycin, suggesting 
that the other mutations confer resistance indirectly by altering in the loop conformation.  
 
1.2.2 Small subunit ribosomal RNA  
 
The ribosomal RNAs (rRNAs) are at the core of the protein synthesis machinery. These RNAs 
were long regarded as mere scaffolds for the r-proteins but recent work has shown that the 
rRNAs in fact carry out the key reactions in translation. A major function of the r-proteins is 
ensuring the correct structure of the rRNA, allowing its tight packing around the active centres of 
the ribosome. In almost all organisms the small ribosomal subunit contains a single RNA species 
(the 18S rRNA in eukaryotes, the 12S rRNA in mitochondria and the 16S rRNA in prokaryotes). 
The 16S rRNA can be divided into four domains, - the decoding region is located at helix 44 
(H44) of Domain IV (Fig. 4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Secondary structure of 16S rRNA from E. coli showing decoding region at helix 44. 
Domain I (blue), Domain II (violet), Domain III (pink), and Domain IV (yellow) are shown. 
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1.3 Eukaryotic Ribosomes  
 
The eukaryotic ribosomes come in two flavors: the cytoplasmic and the mitochondrial ribosomes. 
 
1.3.1 Cytoplasm and cytoplasmic ribosomes 
 
The cytoplasm is the part of a cell that is enclosed within the cell membrane. In eukaryotic cells, 
the contents of the cell nucleus are not part of the cytoplasm and are instead called the 
nucleoplasm. In eukaryotic cells, the cytoplasm contains organelles, such as mitochondria, which 
are filled with liquid that is kept separate from the rest of the cytoplasm by biological membranes. 
The cytoplasm is the site where most cellular activities occur, such as many metabolic pathways 
like glycolysis, and processes such as cell division. The inner, granular mass is called the 
endoplasm and the outer, clear and glassy layer is called the cell cortex or the ectoplasm. 
 
Cytoplasmic ribosomes are present in two forms, free floating and membrane bound (bound to 
the rough endoplasmic reticulum). Human 80S cytoplasmic ribosomes contain 2 subunits i.e., 
small (40S) and large (60S). The small ribosomal subunit contains 18S rRNA and 32 proteins and 
the large subunit comprises the 28S, 5.8S, 5S rRNA and 46 proteins (Table 1).  
 
1.3.2 Mitochondria and mitochondrial ribosomes 
 
Mitochondria are found in all nucleated cells and evolved from a symbiotic relationship between 
aerobic bacteria and primordial eukaryotic cells (56). As the principal generators of cellular ATP 
by oxidative phosphorylation (OXPHOS), these double-membrane organelles provide a highly 
efficient route for eukaryotic cells to generate ATP from energy-rich molecules. Electrons from 
oxidative substrates are transferred to oxygen, via a series of redox reactions. In the process, 
protons are pumped from the matrix across the mitochondrial inner membrane through 
respiratory complexes I, III, and IV. When protons return to the mitochondrial matrix down their 
electrochemical gradient, ATP is synthesized via complex V (ATP synthase). Mitochondria are 
the only location of extra-chromosomal DNA within the eukaryotic cell (except in plant 
chloroplasts), and they are under the dual genetic control of both nuclear DNA and the 
mitochondrial genome. Although the vast majority of mitochondrial proteins (about 900) are 
encoded by the nuclear genome and imported into the mitochondria, mitochondria nevertheless 
maintain a genome that is essential for their respiratory function (56). The mitochondrial genome 
consists of a multicopy, circular dsDNA (mtDNA) molecule (16.6 kb in humans) that contains 37 
genes. Thirteen of these genes encode protein subunits of respiratory complexes I, III, IV, and V; 
only complex II is solely composed of proteins encoded by nuclear genes. The mtDNA genome 
also encodes 22 mitochondrial tRNAs and 2 rRNAs that are essential for translation of mtDNA 
transcripts within the organelle.  
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Human 55S mitochondrial ribosomes contain 2 subunits i.e., small (28S) and large (39S). The 
small ribosomal subunit contains 12S rRNA and 33 proteins and the large subunit comprises the 
16S rRNA and 52 proteins Table 1. Since mitochondria are believed to have arisen from 
endosymbiosis of a eubacterium, it had been assumed that the mitoribosome would be 
structurally closely related to bacterial ribosomes. However, mitochondrial ribosomes have a 
protein-to-RNA ratio of 69% protein:31% RNA, almost a complete reversal of the 33% 
protein:67% RNA in bacterial ribosomes. 
 
1.4 Ribosome as a drug target 
 
Protein synthesis is one of the fundamental processes in all living cells, and therefore, it is not 
surprising that the RNA and protein machinery of the prokaryotic ribosomes are the target of 
about half of the antibiotics characterized thus far (54). Among the different classes of clinically 
important antibiotics that interfere with protein synthesis (Fig. 5) via this target (e.g. 
aminoglycosides, macrolides, ketolides, lincosamides, oxazolidinones and tetracyclines), 
aminoglycosides (Fig. 6) represent gold standard drugs for the treatment of Gram-negative 
pathogens. Streptomycin, the first representative of this class of antibiotics, was discovered by 
Waksman et al. in 1944 and was the first effective antibiotic against Mycobacterium tuberculosis. 
In the following decades several milestone drugs, such as neomycin, kanamycin, tobramycin and 
others, were isolated from soil bacteria by intense search for natural products with antibacterial 
activity (52, 55, 57). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Sites of antibiotic action during protein synthesis. Schematic showing the sites of 
antibiotic action for the different stages of protein synthesis. Figure taken from reference (50). 
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1.4.1 Aminoglycosides 
 
Aminoglycosides form a large family of water-soluble, polycationic amino sugars which are used 
as broad spectrum antibacterial agents (25, 30). Common to all aminoglycosides is the neamine 
core. The neamine core is composed of a sixmembered cyclitol (2-deoxystreptamine; ring II) 
glycosidically linked to a glucopyranosyl (ring I) (19, 39). Additional sugars are attached to 
position 5 or 6 of the 2-deoxystreptamine moiety to give rise to a variety of compounds 
categorized as 4,5- or 4,6- aminoglycosides (Fig. 6). Aminoglycosides target the ribosome by 
direct interaction with ribosomal RNA and they affect protein synthesis by inducing codon 
misreading and by inhibiting translocation of the tRNA-mRNA complex (Fig. 5) (11, 30, 33, 51) 
 
All 2-deoxystreptamine aminoglycosides bind within an internal loop in H44 of the 30S subunit, 
which comprises the decoding site (Fig. 6) (35). This has been observed biochemically by 
chemical probing (31, 32, 60) as well as structurally in complexes of aminoglycosides bound to 
small RNA fragments mimicking H44 (13, 14, 27, 53) as well as to 30S subunit (9, 34, 36) or 70S 
ribosomes (49).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Chemical structures of disubstituted deoxystreptamines, the clinically most relevant 
class of aminoglycosides: (A) 4,5-disubstituted deoxystreptamines; (B) 4,6-disubstituted 
deoxystreptamines. Figure taken from reference (28).  
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The A site of the 30S ribosomal subunit (the decoding centre), in which the codon and anticodon 
pair, is made up of four different domains: the head, shoulder, platform and H44 (Fig. 7A). 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7A: The bacterial decoding center in the 30S ribosomal subunit. Overview of the 30S 
subunit structure, in complex with A-site tRNA anticodon stem–loop (ASL, gold). Red arrows 
indicate the movement of domains during the transition to the closed 30S conformation. P-site 
codon and tRNA-ASL (mimicked by the 3′ end of the 16S RNA and the ‘spur’ stem–loop of a 
symmetry-related molecule in the crystal) are dark grey, helices H44 cyan, and H27 yellow. In 
the shoulder domain, H18 with the 530-loop is turquoise, and proteins S12 (orange), S4 (violet) 
and S5 (dark blue, on the back of the subunit) are highlighted in space-filling representation. In 
the head domain, H34 is blue. Close-up of selected 30S elements around the decoding center, 
showing the A-site codon (purple), 16S RNA nucleotides G530 in the 530-loop (turquoise), and 
A1492 and 1493 in H44 (cyan) the positions of paromomycin (green) and streptomycin (pink). 
Remaining colors as in panel A (proteins S4 and S5 not shown) (35).  
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7B. The bacterial A-site (E. coli numbering) is a well known target for antibiotics. View of 
the three-dimensional structure of the A-site complexed with 4,5- and 4,6-disubstituted 2-
deoxystreptamines: the common neamine core is denoted in yellow; ring III of the 4,6-
compounds (tobramycin) is denoted in red; and rings III and IV of the 4,5-compounds 
(paromomycin) are denoted in blue. Key nucleotides of the binding site are given in bold. 
Figure taken from reference (7). 
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During the last decade, several achievements in bacterial ribosome structure determination (9) 
(47) along with crystal and NMR structures of bacterial A-site oligonucleotide models (14, 54, 59) 
have provided fascinating insights into our understanding of the decoding mechanism in 
prokaryotic cells and of how 2-DOS aminoglycosides induce the deleterious misreading of the 
genetic code. During decoding, a critical step in aminoacyl-tRNA selection is based on the 
formation of a minihelix between the codon of the mRNA and the anti-codon of the cognate 
aminoacyl-tRNA. In this process, the conformation of the A-site is changed from an “off” state, 
where the two conserved adenines A1492 and A1493 are folded back within the helix, to an “on” 
state, where A1492 and A1493 are flipped out from the A-site and interact with the cognate 
codon–anticodon mini-helix (34, 36). This conformational change is a molecular switch that 
irreversibly determines on the continuation of translation. The binding of aminoglycosides such as 
paromomycin to the bacterial A-site changes the conformation equilibrium of the conserved 
adenines A1492 and A1493 by stabilizing the “on” state conformation even in the absence of 
cognate tRNA–mRNA complex (Fig. 8). Thus, the affinity of the A-site for a non-cognate mRNA–
tRNA complex is increased upon aminoglycoside binding, preventing the ribosome from efficiently 
discriminating between near-cognate and cognate complexes and leading to the assembly of 
proteins of incorrect sequence (37). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The molecular basis of the aminoglycoside-induced miscoding as resolved by X-ray 
crystal structures. At the bacterial decoding site (A-site), two flexible adenines A1492 and 
A1493 are in conformational equilibrium with a predominance of an intrahelical “off state” 
conformation. The binding of 2-DOS aminoglycoside paromomycin (green) shifts the 
equilibrium by stabilizing the “on state” conformation even in the absence of mRNA or tRNA. 
In the “on state” conformation the A1492 and A1493 are able to create hydrogen bonds with 
the bases of the mini-helix formed by the near-cognate tRNA anticodon (cyan) and the mRNA 
codon (magenta) leading to miscoding (16). 
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1.4.2 Selectivity and toxicity of Aminoglycosides 
 
Drugs targeting the ribosome are characterized by two features: specificity and toxicity (6, 23, 24, 
38, 40). During the past decades, considerable evidence has accumulated demonstrating that the 
nucleic acid component of the ribosome is key to binding many of the ribosomal drugs, rather 
than the numerous ribosomal proteins (15, 31, 33). Recent data from X-ray crystallography have 
not only confirmed this suggestion but also provided details of drug-target interactions at the 
atomic level by revealing how antibiotic binding occurs (4, 17, 48, 59, 61). 
 
The components of the cytoribosome are encoded by chromosomal genes as are the 
mitoribosomal proteins. However, the rRNA components of the mitoribosome are encoded by the 
mitochondrial genome. Although the basis for drug related toxicity of the ribosomal inhibitors is 
unknown, several lines of evidence point to mitoribosomes as the Achilles heel of ribosomal 
antibiotics, because: (i) mitochondrial ribosomes are more related to the prokaryotic ribosome 
than to the eukaryotic cytoplasmic ribosome; (ii) toxicity in-vivo correlates with activity in-vitro, i.e., 
those antibiotics which exhibit in vitro activity on mitoribosomes are associated with toxicity in 
vivo; (iii) familial hypersensitivity to aminoglycosides (drug-induced deafness) is associated with 
specific mutations in mitochondrial rRNA (43). 
 
It has been suggested that the analysis of drug resistance mutations in bacteria allows one to 
understand the basis of specificity for drugs targeting the ribosome (8). Central to this hypothesis 
is the concept of ‘informative sequence positions’ _ i.e., the identification of polymorphic 
nucleotides as a determinant of drug resistance in bacteria. The identification of a polymorphic 
residue as determinant of ribosomal resistance provides information about the selectivity of a 
ribosomal antibiotic, i.e., whether a drug affects the prokaryotic as opposed to the eukaryotic 
ribosome. The basis for this hypothesis was initially established by investigating bacterial 
alterations within the ribosome mediating resistance to aminoglycosides. The conclusion from 
these studies was that the selectivity of these agents is largely due to a single nucleotide position 
within the rRNA, e.g., the identity of the base at 16S rRNA position 1408. According to this 
hypothesis, selectivity of the aminoglycosides is due to the natural insensitivity of eukaryotic 
cytoplasmic ribosomes conferred by a guanine at 16S rRNA position 1408; conversely the toxicity 
of aminoglycosides (at least irreversible ototoxicity) is due to the natural susceptibility of 
mitoribosomes, which carry a susceptible bacterial adenine at this sequence position (Fig. 9) (8). 
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Figure 9.  16S rRNA decoding region: secondary structures. 
 
1.5 Ribosomal dysfunction in Mitochondria 
 
Mitochondria are vital components of all nucleated cells. Mitochondrial diseases are a clinically 
heterogeneous group of disorders that arise as a result of dysfunction of the mitochondrial 
respiratory chain. They can be caused by mutations of nuclear DNA or mitochondrial DNA 
(mtDNA). Nuclear gene defects may be inherited in an autosomal recessive manner or an 
autosomal dominant manner. Mitochondrial DNA defects are transmitted by maternal inheritance. 
A male does not transmit the mtDNA mutation to his offspring. Some mitochondrial disorders only 
affect a single organ (such as the eye in Leber hereditary optic neuropathy [LHON]), but many 
involve multiple organ systems and often present with prominent neurologic and myopathic 
features. Mitochondrial dysfunction has pleiotropic effects in multicellular organisms. 
Mitochondrial disorders may present at any age. In general terms, nuclear DNA mutations 
present in childhood and mtDNA mutations (primary or secondary to a nuclear DNA abnormality) 
present in late childhood or adult life. Common clinical features of mitochondrial disease include 
ptosis, external ophthalmoplegia, proximal myopathy and exercise intolerance, cardiomyopathy, 
sensorineural deafness, optic atrophy, pigmentary retinopathy, and diabetes mellitus.  
 
Mutations in the decoding A-site of mitochondrial 12S rRNA have been associated with deafness 
(2, 3). In particular, the single-nucleotide alterations A1555G and C1494U have been identified as 
a major source of nonsyndromic deafness (43, 62). By themselves, these mutations produce a 
clinical phenotype that may range from severe congenital deafness through moderate 
progressive hearing loss of later onset to normal hearing (12). Interestingly, and in addition to the 
genetic predisposition, mutations A1555G and C1494U render affected individuals 
hypersusceptible to aminoglycoside autotoxicity. 
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1.6 Model system 
 
Investigations on structure-function relationships of mitochondrial rRNA in higher and lower 
eukaryotes are mainly hampered by the lack of experimental genetic models (18, 19, 21, 22). 
Genetic manipulation of the rRNA component of eukaryotic ribosomes has proven exceedingly 
difficult due to the high copy number of corresponding operons. Higher eukaryotes have so far 
resisted any genetic manipulation of their ribosomal nucleic acids, virtually abolishing the 
possibility to test hypotheses by experimentation. Even most eubacteria harbor multiple rRNA 
operons (e.g. E. coli: 7; Bacillus subtilis: 10; Streptomyces ambofaciens: 4) making genetic 
studies of rRNA difficult. In the mid 90s, genetic procedures were developed which permitted the 
construction of eubacteria carrying a single functional rRNA operon (46) (1). These single rRNA 
allelic microorganisms allow mutagenesis of their ribosomal nucleic acids to result in cells 
containing homogeneous populations of mutant ribosomes (42).  
 
In the present thesis, and with the view to study the interaction of aminoglycoside antibiotics with 
eukaryotic ribosomes, we replaced a central 34-nucleotide part of the bacterial drug binding 
pocket in 16S rRNA H44 of Mycobacterium smegmatis with its eukaryotic counterpart, resulting in 
bacterial hybrid ribosomes with a fully functional eukaryotic rRNA decoding site. For this, the 
recently described M. smegmatis mc2 155 ΔrrnB (20) was used for all genetic manipulations. 
Using a strategy of unmarked deletion of chromosomal rRNA operons combined with RecA 
mediated site-directed mutagenesis, the decoding region was engineered.  
 
For functional characterization of these hybrid ribosomes and to study a possible cause-effect 
relationship of disease-associated mitochondrial rRNA mutations, we assessed drug susceptibility 
in-vivo, by minimal inhibitory concentration assays. We also studied translational activity, drug 
susceptibility, drug induced misreading, and decoding accuracy in-vitro by cell free translation 
assays.  
 
The model system was used to: 
 
i) test the effect of ribosomal antibiotics on translation. 
ii) identify mode of action of drugs and their interaction with ribosomes.  
iii) study structure-function relationships within a defined region of  rRNA. 
iv) investigate the influence of rRNA mutations on protein synthesis. 
v) investigate disease associated alterations in the small subunit rRNA. 
vi) determine residues critical for selectivity and specificity of aminoglycosides. 
vii) compare the functionality of humanized hybrid ribosomes to that of eukaryotic 
cytoplasmic ribosomes. 
viii) study the functionality of hybrid protozoan parasitic ribosomes 
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ABSTRACT
Structural and genetic studies on prokaryotic
ribosomes have provided important insights into
fundamental aspects of protein synthesis and
translational control and its interaction with riboso-
mal drugs. Comparable mechanistic studies in
eukaryotes are mainly hampered by the absence of
both high-resolution crystal structures and efficient
genetic models. To study the interaction of amino-
glycoside antibiotics with selected eukaryotic ribo-
somes, we replaced the bacterial drug binding site
in 16S rRNA with its eukaryotic counterpart, result-
ing in bacterial hybrid ribosomes with a fully
functional eukaryotic rRNA decoding site. Cell-free
translation assays demonstrated that hybrid ribo-
somes carrying the rRNA decoding site of higher
eukaryotes show pronounced resistance to amino-
glycoside antibiotics, equivalent to that of rabbit
reticulocyte ribosomes, while the decoding sites of
parasitic protozoa show distinctive drug suscept-
ibility. Our findings suggest that phylogenetically
variable components of the ribosome, other than the
rRNA-binding site, do not affect aminoglycoside
susceptibility of the protein-synthesis machinery.
The activities of the hybrid ribosomes indicate
that helix 44 of the rRNA decoding site behaves as
an autonomous domain, which can be exchanged
between ribosomes of different phylogenetic
domains for study of function.
INTRODUCTION
Accurate decoding of genetic information is a crucial step
in protein synthesis. Genetic, biochemical and structural
data provide evidence for a functional role of ribosomal
RNA in mRNA decoding and tRNA selection (1–3).
The functional relevance of rRNA residues in
codon–anticodon recognition and stabilization is reflected
in their universal conservation throughout the three
phylogenetic domains of life. While this holds true for
most nucleotides in helices 18, 34 and 44 of the small
subunit rRNA that form the aminoacyl-tRNA acceptor
site (A site), critical variations have evolved between
different phylogenetic domains, most prominent in helix
44, the penultimate stem of 16S rRNA (4). These
variations most likely account for a decoding region that
has been highly optimized in the context of evolutionary
differentiation.
Aminoglycosides are a class of structurally related
antibiotics which interfere with decoding by binding to
the A site of small subunit rRNA (5). These antibiotics
preferentially target prokaryotic over eukaryotic ribo-
somes and affect protein synthesis by inducing codon
misreading and inhibiting tRNA translocation (6–8).
The binding site is located within a conserved loop of
helix 44, which in part shows phylogenetic sequence
variability, e.g. at position 1408 and at base pair
1409–1491 (9) (rRNA residues are numbered according
to Escherichia coli nomenclature; see also Figure 2).
Crystal structures of various bacterial 30S ribosomal
particles in complex with different ligands, e.g. tRNA and
antibiotics, have revealed the molecular mechanisms of the
decoding step at atomic resolution (10,11). In the absence
of high-resolution X-ray crystal structures of eukaryotic
ribosomes, model oligonucleotides mimicking the riboso-
mal decoding site have been used for structural analysis
of the A site in human cytosolic ribosomes (12).
Site-directed mutagenesis has been used in prokaryotes
to study the functional relevance of individual drug–
nucleotide contacts in aminoglycoside–ribosome interac-
tion (13). A detailed analysis of the aminoglycoside
target site in ribosomes of higher and lower eukaryotes
is complicated by the complexity of eukaryotic rRNA
genetics. Genetic manipulation of the rRNA component
of eukaryotic ribosomes has proven exceedingly difficult
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due to the problem of the high copy number of
corresponding operons. Higher eukaryotes have so far
resisted any genetic manipulation of their ribosomal
nucleic acids, virtually abolishing the possibility to test
hypotheses by experimentation. Even in lower eukaryotic
organisms, such as yeast, the presence of 100–200
tandemly repeated copies at the RDN locus, has made
genetic studies of rRNA difficult (14–16).
The eukaryotic ribosome differs significantly from
the prokaryotic one (17). It is impossible to predict the
contribution of additional, phylogenetically diverse ribo-
somal elements and characteristics, as in the eukaryotic
ribosome, to aminoglycoside susceptibility. It is, for
instance, commonly assumed that translation in mamma-
lian cells functions with higher fidelity than that of
bacteria (18). To address this question experimentally,
we have performed domain shuffling experiments in
rRNA. Using genetic techniques, we successfully engi-
neered a functionally critical domain in the ribosome by
replacing the bacterial A-site rRNA of helix 44 with its
counterpart from higher and lower eukaryotes. For
functional characterization of these hybrid ribosomes,
we studied their susceptibility to antibiotics targeting the
ribosomal A site and which are known to affect bacterial
versus eukaryotic ribosomes to different extents.
MATERIALS AND METHODS
Construction of the rrn plasmid exchange system
Starting with Mycobacterium smegmatis mc2-155 SMR5
(19), a single-rRNA allelic strain bearing a deletion of
5 kb in the chromosomal rrnA operon was constructed
by gene replacement. The deletion strategy for chromo-
somal rRNA operons is shown in Supplementary
Figure 1. Subsequently and following integration of the
rrnB-replacement vector into the chromosomal rrnB locus,
the strain was transformed with integration-proficient
vector pMIH-rrnB2058G for rRNA complementation.
pMIH-rrnB2058G is a derivative of plasmid pMV361-
rrnB2058G (20), in which the kanamycin resistance cassette
has been replaced with a hygromycin resistance cassette.
Counterselection and genetic screening for deletion of the
chromosomal rrnB locus resulted in strain M. smegmatis
rrn pMIH-rrnB2058G bearing unmarked full deletions
of the chromosomal rrnA and rrnB loci. In this strain,
ribosomal RNA is exclusively transcribed from the
complementation vector (Figure. 1).
To establish a genetic system for efficient plasmid
exchange, an integration-proficient complementation
vector pMIG-rrnB-sacB was designed that carries the
rrnB wild-type operon, a gentamicin resistance cassette,
T
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rrsB rrlB 3760tyrS rrfB
P T
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T
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murA‘rrfA ogt
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M. smegmatis
∆rrnA
∆rrnA attB::pMIH-rrnB2058G
∆rrnA ∆rrnB attB::pMIH-rrnB2058G
∆rrnA ∆rrnB attB::pMIG-sacB-rrnB2058G
∆rrnA ∆rrnB attB::pMIH-rrnBhybrid
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Chromosomal locus
Figure 1. Sequential strategy for the generation of a plasmid-rRNA exchange system. From top: Following deletion of chromosomal rrnA,
a complementation vector pMIH-rrnB2058G carrying a functional rrn operon was introduced to the chromosomal attB site. Subsequent deletion of
rrnB resulted in M. smegmatis rrnA rrnB attB::pMIH-rrnB2058G, in which ribosomal RNA is exclusively transcribed from the plasmid. From
there, a plasmid-rRNA exchange system was established by replacing pMIH-rrnB2058G with pMIG-rrnB-sacB. Transformation with hybrid rRNA
genes pMIH-rrnBhybrid and selection on sucrose resulted in M. smegmatis rrnA rrnB attB::pMIH-rrnBhybrid with homogenous populations
of hybrid ribosomes.
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and the sucrose sensitivity marker sacB. This vector was
used to replace pMIH-rrnB2058G in strain M. smegmatis
rrn pMIH-rrnB2058G, resulting in strain M. smegmatis
rrn pMIG-rrnB-sacB. The latter was used as plasmid
exchange system in which the rrnB wild-type operon can
be efficiently replaced with an rrnB mutant operon by
transformation and selection on sucrose-containing media
(Figure. 1).
Construction of mutant strains with hybrid ribosomes
Site-directed mutagenesis of rRNA genes was performed
by PCR mutagenesis as described previously (21). In
brief, hybrid rDNA oligonucleotides comprising the
eukaryotic helix 44 decoding site sequence were used for
gene amplification. Using restriction endonuclease recog-
nition sites present in the operon, rRNA gene fragments in
plasmid pMIH-rrnB were replaced to construct pMIH-
rrnBhybrid, the plasmids coding for hybrid 16S rRNA
genes. Mycobacterium smegmatis rrn pMIG-rrnB-sacB
was transformed with the various pMIH-rrnBhybrid
constructs and selected on hygromycin plates containing
sucrose (Figure 1). Successful plasmid exchange was
controlled by sequence analysis.
Minimal inhibitory concentrations
Broth microdilution tests were performed in a microtiter
plate format as described previously (22). In brief,
bacterial strains were cultured on Luria–Bertani (LB)
agar plates at 378C. Freshly grown cultures were
resuspended in LB broth supplemented with 0.05% of
Tween 80, diluted to an absorbance at 600 nm of 0.025,
and incubated in the presence of 2-fold serial dilutions
of the following 2-deoxystreptamine aminoglycosides:
paromomycin, neomycin, geneticin (G418), gentamicin,
netilmicin, tobramycin and kanamycin A (Sigma). After
incubation at 378C for 72 h, the minimal inhibitory
concentration (MIC) was recorded as the lowest concen-
tration of drug inhibiting visible growth.
Ribosome purification
Approximately 8 g of wet bacterial cell mass were
resuspended in 25ml of homogenization buffer (HB;
20mM Tris–HCl pH 7.4, 100mM NH4Cl, 10.5mM
MgCl2, 0.5mM EDTA and 3mM 2-mercaptoethanol)
and lyzed with a French Pressure Cell (American
Instrument Company, Maryland) at 16 000 psi, as
described previously (23). The lysate was supplemented
with DNase (RQ1 RNase-free, Promega, 2 U per gram
cell mass), incubated on ice for 10min, and adjusted with
HB to a volume of 70ml. Pre-cooled alumina (1.5 g per
gram cell mass) was added to the cell lysate, stirred on ice
for 20min, and removed by low-speed centrifugation
(10min at 2000g; all centrifugations were performed at
48C). Cell debris was sedimented by centrifugation for
30min at 10 000g and the lysate was passed through a tea
filter. Centrifugation of the lysate for 60min at 32 500g
resulted in the S-30 supernatant. Sixteen milliliter portions
of the supernatant were layered on 9ml sucrose cushions
(SC; 20mM Tris–HCl pH 7.4, 350mM NH4Cl, 10.5mM
MgCl2, 0.5mM EDTA, 1.1M sucrose and 3mM
2-mercaptoethanol) and centrifuged for 15 h at 110 000g
(Beckman Coulter OptimaTM L-80 XP Ultracentrifuge) to
separate ribosomal particles from the S-100 supernatant.
The S-100 fraction was dialyzed for 24 h (6000–8000
MWCO, Spectra/Por, Serva) with three intermittent
changes of buffer A (50mM Tris–HCl pH 7.5, 70mM
NH4Cl, 30mM KCl and 7mM MgCl2), concentrated
(Viva spin, 10 000 MWCO, Viva Science), and stored at
808C. Ribosome pellets from the S-100 preparation were
resuspended in washing buffer (WB; 20mM Tris–HCl pH
7.4, 350mM NH4Cl, 10.5mMMgCl2, 0.5mM EDTA and
7mM 2-mercaptoethanol) and passed twice through
sucrose cushions (6 h at 180 000g and 16 h at 83 000g).
The final ribosome pellets were resuspended in buffer A,
incubated for 30min at 48C, dispensed into aliquots, and
stored at 80C after shock freezing in liquid nitrogen. 70S
ribosome concentrations were determined by absorption
measurements on the basis of 23 pmol per A260 unit.
Qualitative evaluation of ribosome preparations
Integrity of 70S ribosomes was determined by analytical
ultracentrifugation (14 h at 70 000g) through a 10–40%
sucrose gradient in both association buffer (buffer A) and
dissociation buffer (50mM Tris–HCl pH 7.5, 70mM
NH4Cl and 30mM KCl). 70S, 50S and 30S ribosome
fractions in different gradient layers were detected and
quantified by absorption at 254 nm. Functional activity of
purified ribosomes was determined by assessing their
capacity to form initiation complexes. 70S ribosomes
(0.5 mM) were incubated in buffer A with m022 SD-MFTI-
mRNA at 1.5 mM (50-GGCAAGGAGGUAAAUAAUG
UUCACGAUC-30; obtained from Dharmacon), initiation
factors (IF) 1 and 3 from M. smegmatis, IF-2 from E. coli
(1 mM each), GTP (1mM), and [3H]-fMet-tRNAfMet
(1 mM) for 60min at 378C; purified tRNA and IF2
from E. coli were a kind gift from Marina Rodnina.
The initiation complexes formed were bound to nitrocel-
lulose filters (Sartorius, pore size 0.45mm), washed with
15ml cold buffer A, dissolved in 10ml scintillation
cocktail (Filtersafe, Zinsser Analytic) and quantified in a
Liquid Scintillation Analyzer (Tri-Carb 2900 TR,
PerkinElmer).
Cell-free (UUU)12 translation assays
Cell-free translation reactions in buffer A (pH 7.5) were
prepared on ice and contained M. smegmatis tRNAbulk
(0.5mg/ml), amino acids mixture (30mM each) lacking
phenylalanine and/or leucine, 10% (v/v) S100 extract,
energy mix [DTT (1mM), GTP (1mM), ATP (4mM),
PEP (5mM)], pyruvate kinase (0.1mg/ml), and polya-
mines [spermidine (2mM) and putrescine (8mM)].
The reaction mixture was preincubated with radiolabeled
phenylalanine and/or leucine (30mM; obtained from
Amersham) at 378C for 15min. The translation reaction
was started by addition of ribosomes to a final concentra-
tion of 0.25mM and (UUU)12-mRNA (50-GCGGCAA
GGAGGUAAAUA AUG (UUU)12 UAA GCAGG-3
0,
obtained from Dharmacon) to 1 mM; serially diluted
aminoglycoside antibiotics were added simultaneously.
Following incubation at 378C for 60min, the reaction was
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stopped by addition of KOH to 0.5M and subsequent
hydrolysis at 378C for 30min. Synthesized polypeptides
were precipitated with 200 ml of 5% tri-chloro-acetic acid
(TCA) for 10min on ice and bound to nitrocellulose filters
(Sartorius, pore size 0.45 mm). Filter-bound polypeptides
were washed with cold 30% 2-propanol and quantified
in 10ml of scintillation cocktail. Data analysis was
performed with Prism (GraphPad Software Inc.). Best-fit
nonlinear regression was used to define the 100% value of
polypeptide synthesis and to calculate the aminoglycoside
IC50 values of dose-dependent inhibition (Figure 3
and Table 2).
Cell-free luciferase translation assays
Purified 70S hybrid ribosomes were used in a coupled
transcription–translation reaction of firefly luciferase
(plasmid pBESTluc, Promega). A typical reaction
(15 ml volume) contained 0.25 mM 70S ribosomes, 300 ng
DNA, 40% (v/v) of M. smegmatis S100 extract, 100 mM
amino acid mixture, and RNasin (40 U, Promega). rNTPs,
tRNAs and energy were supplied by addition of commer-
cial S30 Premix Without Amino Acids (Promega). Serially
diluted aminoglycosides were added and the reaction
mixture was incubated at 378C for 60min. The reaction
was stopped on ice, 100 ml of luciferase assay substrate
(Promega) was added, and the bioluminescence was
measured in a luminometer (Bio-Tek instruments,
FLx800). Data analysis was performed with Prism
(GraphPad Software Inc.). Best-fit nonlinear regression
was used to define the 100% value of luciferase synthesis
and to calculate the aminoglycoside IC50 values of dose-
dependent inhibition (Figure 4 and Table 3).
Rabbit reticulocyte translation assays
Cytosolic ribosomes present in commercially available
rabbit reticulocyte lysate (Promega) were used for in vitro
translation of a firefly luciferase control mRNA
(Promega). A standard 30 ml reaction contained 20 ml
reticulocyte lysate, 500 ng of luciferase mRNA, an amino
acid mixture (100mM each), and RNasin. Serially diluted
aminoglycosides were added and the reaction mixture was
incubated at 308C for 90min. After incubation, 100 ml
of luciferase assay substrate (Promega) was added and
luciferase activity was determined.
RESULTS AND DISCUSSION
The two chromosomal rrn operons in M. smegmatis were
inactivated to produce a strain in which ribosomal RNA
is exclusively transcribed from plasmid-encoded rRNA
genes. Operon inactivation was achieved by means of
unmarked deletion mutagenesis spanning the complete
rRNA gene sequences and part of the promoter region
(Supplementary Figure 1). For complementation, a fully
functional wild-type rrnB operon encompassing promoter
and termination sequences was cloned into the integra-
tion-proficient plasmid pMIG-sacB. In M. smegmatis
rrn pMIG-sacB-rrnB, the wild-type rRNA operon
carried on pMIG-sacB is efficiently replaced with a
mutant rRNA operon by plasmid exchange following
transformation with integration-proficient plasmid pMIH-
rrnBmut (for details, see the Materials and Methods section
and Figure 1). The rRNA plasmid exchange system was
used to replace the bacterial 16S rRNA helix 44 within the
decoding region with its homologous structures from
parasitic kinetoplastid protozoa. The kinetoplastid genera
Leishmania and Trypanosoma comprise species that are
responsible for leishmaniasis and trypanosomiasis,
diseases that are widespread in many tropical and sub-
tropical countries. The insect trypanosome Blastocrithidia
is characterized by an rRNA decoding site with an adenine
at the position homologous to 16S rRNA residue 1408,
and therefore represents a very rare trait within the
eukaryotic domain. We also constructed human–bacterial
hybrid ribosomes by introducing the human helix 44
rRNA homolog into functional ribosomes of strain
M. smegmatis rrnB by a method described previously
(13). Both approaches resulted in bacterial mutant strains
with homogenous populations of hybrid ribosomes in
which a 34 nucleotide portion of helix 44 was substituted
with its counterpart of eukaryotic small-subunit rRNA
(Figure 2). Together with A-site residues in helices 18, 34
and 44 that are universally conserved throughout the
phylogenetic domains, the engineered decoding site
resembles that of eukaryotic cytosolic ribosomes.
Engineering the eukaryotic decoding sites into bacterial
ribosomes had relatively little effect on cell growth, with
only slightly increased generation times as compared to
wild-type cells (generation times: wild-type 3.7 0.3 h;
Leishmania hybrids 4.8 0.5 h; Blastocrithidia hybrids
4.2 0.1 h; H. sapiens hybrids 5.1 0.6 h).
A bacterial oligoribonucleotide analog of 16S rRNA
helix 44 has been shown to interact with both antibiotic
and RNA ligands of the 30S subunit in a manner that
correlates with normal subunit function (24). Since the
decoding-site rRNA in the hybrid ribosomes is identical to
that of eukaryotic ribosomes, the hybrid ribosomes may
serve as a model to investigate specific features associated
with the eukaryotic A-site rRNA structure. Towards this
end, we investigated the susceptibility of the hybrid
ribosomes to the 2-deoxystreptamine antibiotics paromo-
mycin, neomycin, geneticin (G418), gentamicin, netilmi-
cin, tobramycin and kanamycin A (see Supplementary
Figure 2 for chemical structures). In MIC assays, which
determine growth inhibition at the whole cell level,
M. smegmatis mutants carrying human–bacterial hybrid
ribosomes were highly resistant to all aminoglycoside
antibiotics tested except for geneticin (Table 1). Relative
resistance of the human hybrids to geneticin, calculated
as the ratio of mutant to wild-type MIC, was 8 to 16 as
compared to  1024 for paromomycin, neomycin, genta-
micin, netilmicin, tobramycin, and kanamycin. The
Leishmania hybrids showed high-level resistance to
neomycin, gentamicin, netilmicin, tobramycin and kana-
mycin, with relative resistance levels of 1024. However,
the Leishmania hybrids showed distinct susceptibility to
paromomycin and geneticin, i.e. aminoglycosides with
a hydroxyl group at position 60 of ring I. Mycobacterium
smegmatis hybrids with a Blastocrithidia decoding region
were susceptible to all aminoglycoside antibiotics;
the minimal inhibitory concentrations of the 4,6- and
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4,5-disubstituted deoxystreptamines against
Blastocrithidia hybrids were similar to those observed for
the wild-type M. smegmatis strain (Table 1).
To analyze the antibiotic effects on translation in more
detail, we determined the IC50 values for selected
aminoglycosides in (UUU)12-mRNA-directed phenylala-
nine incorporation in cell-free translation assays. In vitro
translation assays were established with purified 70S
ribosomes of wild-type and mutant M. smegmatis strains.
A polyphenylalanine mRNA with a ribosomal-binding
site, twelve consecutive (UUU) triplets coding for
phenylalanine, and a stop codon was used to assess
aminoglycoside-induced inhibition of [14C]-phenylalanine
incorporation in translating wild-type and hybrid ribo-
somes. Bacterial wild-type ribosomes were highly suscep-
tible to all aminoglycosides tested, with IC50 values for
poly-Phe synthesis below 3 mM (Figure 3 and Table 2).
Hybrid ribosomes with a Blastocrithidia decoding region
were likewise susceptible to low aminoglycoside concen-
trations. In contrast, hybrid ribosomes with the human
decoding site were resistant, exhibiting IC50 values that are
more than 500-fold higher than those observed in bacterial
wild-type ribosomes. Leishmania hybrid ribosomes were
resistant to all aminoglycosides tested except paromomy-
cin. In order to assess aminoglycoside-stimulated mis-
reading (25) in hybrid ribosomes, paromomycin was used
U
A
A
A
AC
U
G C
C
C G
G C
U
C G
C A
A
AA
C G
G C
A
G
U A
GU ·
A
C
1410 1490
1420 1480
1400
1500
C G
G C
C G
G U
A G
U G
A U
G
A GUA
C
·
·
U
A
A
A
AC
U
G C
C
C G
G C
U
C G
C A
A
AG
C G
G C
A
G
A U
GU ·
A
C
1410 1490
1420 1480
1400
1500
C A
U A
C G
C G
U A
A A
C G
G
A GUA
C
C G
GC
UA
U
A
A
A
AC
U
G C
C
C G
G C
U
C G
C A
A
AG
C G
G C
A
G
G C
GU ·
A
C
1410 1490
1420 1480
1400
1500
U A
U A
U G
U A
U A
G
A G
C
·
C G
GC
U
A
A
A
AC
U
G C
C
C G
G C
U
C G
C A
A
AA
C G
G C
A
G
G C
GU ·
A
C
1410 1490
1420 1480
1400
1500
U A
U A
U G
U A
U A
G
A GUA
C
·
A B C D
M. smegmatis Homo sapiens Leishmania 
Trypanosoma
Blastocrithidia
Figure 2. 16S rRNA sequence within helix 44 of M. smegmatis wild-type and hybrid ribosomes after transplanting the A-site rRNA of eukaryotic
ribosomes. (A) Mycobacterium smegmatis. (B) Human–bacterial hybrid ribosomes. (C) Hybrid ribosomal RNA containing the decoding-site rRNA
of the protozoan Leishmania, which is also identical to Trypanosoma; and (D) Blastocrithidia. Base substitutions rendering the bacterial 16S rRNA
eukaryotic are depicted in blue; the transplanted region is boxed. rRNA residues are numbered according to the nucleotide numbering used in E. coli
16S rRNA.
Figure 3. Kanamycin-induced inhibition of polypeptide synthesis using (UUU)12-directed phenylalanine incorporation. (A) Homo sapiens cytosolic
hybrid ribosomes (closed circles) versus M. smegmatis wild-type ribosomes (open circles). (B) Leishmania (closed squares) versus Blastocrithidia (open
squares) hybrid ribosomes. The relative amount of [14C]-phenylalanine incorporated by 5 pmol of purified 70S ribosomes after 60min. incubation in
the presence of varying concentrations of kanamycin A is shown. SEs are indicated. The corresponding IC50 values for kanamycin A and selected
aminoglycoside antibiotics are given in Table 2.
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to measure drug-induced incorporation of leucine in a
cell-free (UUU)12 translation assay. In line with the other
assays used to determine ribosomal drug susceptibility,
the Leishmania hybrids were significantly more susceptible
to paromomycin-induced mistranslation than the human
hybrids (data not shown).
We next wished to validate the hybrid ribosome
approach by comparing the human–bacterial hybrid
ribosomes to rabbit reticulocyte ribosomes (the decoding-
site rRNA of human cytosolic ribosomes is identical to
that of most vertebrates, including rabbit). In addition,
with a view to define the selectivity of aminoglycoside
compounds for protozoan versus human ribosomes more
accurately, we wished to use an assay which is not limited
by its sensitivity. Note that both the whole-cell determina-
tion of minimal inhibitory concentrations (MIC; Table 1)
and the (UUU)12 assay using purified ribosomes (Table 2)
are limited by the amount of drug which can be applied.
Towards this end we analyzed synthesis of luciferase based
upon a coupled transcription–translation assay. Figure 4
shows the effect of paromomycin on protein synthesis
in bacterial versus human–bacterial hybrid ribosomes
and compared to rabbit reticulocyte ribosomes translating
a luciferase mRNA. The paromomycin concentration
required to inhibit synthesis of active luciferase in human-
hybrid ribosomes to 50% (IC50) closely resembled the IC50
Table 3. Aminoglycoside-induced inhibition of luciferase synthesis
Compound IC50 (mM)
a
Mycobacterium
smegmatis
Homo sapiens Leishmania
Trypanosoma
Blastocrithidia Rabbit reticulocyte
lysateb
Paromomycin 0.03 4.7 0.18 0.05 9.2
Neomycin 0.04 13 6.7 0.05 18
Geneticin 0.03 0.8 0.02 0.02 0.2
Netilmicin 0.05 64 127 0.11 58
Tobramycin 0.02 21 60 0.05 38
Kanamycin A 0.05 116 204 0.03 67
aAminoglycoside concentrations required to inhibit synthesis of active luciferase to 50 percent (IC50). Inhibition kinetics are exemplified by the graphs
for paromomycin presented in Figure 4. Best-fit nonlinear regression was used to define the 100% value and to calculate the IC50.
bThe rRNA decoding region of rabbit reticulocyte ribosomes is identical to that of human cytosolic ribosomes shown in Figure 2B.
Table 2. Aminoglycoside-induced inhibition of (UUU)12-directed
phenylalanine incorporation
Compound IC50 (mM)
a
Mycobacterium
smegmatis
Homo
sapiens
Leishmania
Trypanosoma
Blastocrithidia
Paromomycin 0.9 >500 96 2.7
Neomycin 0.4 >500 >500 0.7
Gentamicin 0.7 >500 >500 0.7
Netilmicin 0.7 >500 >500 1.1
Tobramycin 1.0 >500 >500 2.3
Kanamycin A 2.5 >500 >500 7.5
aAminoglycoside concentrations required to inhibit [14C]-phenylalanine
incorporation to 50 percent (IC50). Inhibition kinetics are exemplified
by the graphs for kanamycinA presented in Figure 3. Best-fit nonlinear
regression was used to define the 100% value and to calculate the IC50.
An antibiotic concentration of 1 mM corresponds to approximately four
aminoglycoside molecules per ribosome.
Figure 4. Paromomycin-induced inhibition of protein synthesis
measured as luciferase activity in cell-free translation assays of firefly
luciferase mRNA. Rabbit reticulocyte (closed triangles) versus human-
bacterial hybrid (closed circles) and wild-type M. smegmatis (open
circles) ribosomes; error bars represent the SEM (n=3). The
corresponding IC50 values for paromomycin and the aminoglycosides
tested are given in Table 3.
Table 1. Activity of aminoglycoside antibiotics against cells carrying
hybrid ribosomes
Compound MIC (mg/ml)
Mycobacterium
smegmatis
Homo
sapiens
Leishmania
Trypanosoma
Blastocrithidia
Paromomycin 1 1024 128 4
Neomycin 0.5 >1024 >1024 1
Geneticin 8 128 4 4
Gentamicin 1 >1024 >1024 1
Netilmicin 2 >1024 >1024 8
Tobramycin 1 1024 1024 2
Kanamycin A 1 >1024 >1024 1
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in rabbit reticulocyte lysate. In fact, the IC50 values of the
human hybrid ribosomes are virtually identical to the IC50
values determined for rabbit cytosolic ribosomes for all
aminoglycosides tested in this study (Table 3). In contrast,
the IC50 values in bacterial ribosomes were two to three
orders of magnitude lower. Thus, transplanting helix 44 of
the eukaryotic decoding region into bacterial ribosomes
testified to be a valid approach for studying the specificity
of aminoglycoside antibiotics, compounds that selectively
affect prokaryotic versus eukaryotic ribosomes.
Analysis of aminoglycoside-induced inhibition of
luciferase synthesis in Leishmania hybrid ribosomes and
comparison to human hybrid ribosomes also allowed
quantifying the differences in drug susceptibility.
Leishmania hybrid ribosomes are 20- to 30-fold
more susceptible to the 4,5-disubstituted aminoglycoside
paromomycin than human hybrid ribosomes. In line with
the results from MIC determinations (Table 1) and
aminoglycoside-induced inhibition of (UUU)12-driven
phenylalanine incorporation (Table 2), there is a significant
difference in drug susceptibility between Leishmania hybrid
and human hybrid ribosomes for aminoglycosides with a
60-hydroxyl group. This is in contrast to aminoglycosides
with a 60-amino group where no such difference is present.
The basic mechanisms of translation of mRNA to
protein are conserved throughout all organisms (17,26).
Experimental data suggest that the selectivity of amino-
glycoside antibiotics for bacterial ribosomes is due to
defined phylogenetic variations of ribosomal RNA in an
otherwise highly conserved binding site (13). The results
obtained with the hybrid ribosomes are in excellent
agreement with the drug susceptibilities determined in
rabbit reticulocyte lysate (Table 3) and with data reported
in the literature on complete eukaryotic ribosomes (25,27),
demonstrating that the model system adequately reflects
the situation in eukaryotic cytosolic ribosomes. Drugs
targeting protein synthesis are infrequently used for
treatment of infections with lower eukaryotes such as
protozoan parasites, helminths or fungi, although the
potential for selective activity appears to exist (28–33).
Using various assays of drug activity, we demonstrated
that the 4,5-disubstituted aminoglycoside paromomycin
exhibits a distinct activity towards hybrid ribosomes
carrying the cytosolic decoding site of Leishmania and
Trypanosoma. These results provide an explanation for the
activity of paromomycin in treatment of leishmaniasis
(34,35), by pointing to the cytosolic ribosome as a drug
target. Little treatment options involving quite toxic
drugs, such as the trivalent arsenic compound melarso-
prol, exist for late stage T. brucei rhodiense sleeping
sickness (36). The availability of compounds with anti-
trypanosomal activity would be most significant, if only as
second-line option for patients who experience relapse.
Defined point mutations have been introduced pre-
viously into the bacterial rRNA A site to study individual
drug—nucleotide interactions of aminoglycosides (13).
These studies demonstrated the role of nucleotides 1408,
1409 and 1491 in drug binding. A base substitution of
adenine at position 1408 with a guanine interrupts the
pseudo-base-pair formation of the adenine with ring I of
the disubstituted 2-deoxystreptamines and alterations of
the 1409–1491 bp interfere with the stacking interaction
between 1491 and ring I. Our study complements this
reductionistic approach by transferring the complete
eukaryotic binding site into bacterial ribosomes. Given
the complex structure of the ribosome and its various
components that contribute to translational fidelity, e.g.
ribosomal proteins S4, S5 and S12 (3), it is remarkable
that a hybrid bacterial ribosome carrying the eukaryotic
H44 shows a drug-susceptibility pattern identical to that
of complete rabbit reticulocyte ribosomes. From this we
conclude that additional phylogenetically variable riboso-
mal structures do not affect aminoglycoside susceptibility
of the complete eukaryotic ribosome. In line with previous
findings (13,37–39), a more general picture emerges, where
ribosomes with a 1408 guanine in small subunit rRNA are
resistant to aminoglycosides carrying an amino group at
position 60 of ring I (neomycin, gentamicin, netilmicin,
tobramycin, kanamycin), while A sites with a non-
canonical base-pair interaction between residues 1409
and 1491 are predominantly resistant to geneticin and
paromomycin, drugs which carry a hydroxyl group at the
60 position of ring I. Together, these results suggest that
paromomycin and geneticin have a specific activity against
ribosomes that are characterized by a canonical 1409–
1491 bp; that neomycin, gentamicin, netilmicin, tobramy-
cin and kanamycin are active against ribosomes with a
1408 adenine; and that metazoan cytosolic ribosomes are
generally resistant to 2-deoxystreptamines.
Successful crystallizations of the ribosome and ribo-
some–drug complexes have initiated a rebirth of interest in
the ribosome as drug target (40–43). Apparently, helix 44
of the rRNA decoding A site behaves as an autonomous
domain, which can be dissected from the remaining part of
the ribosome and shuffled between ribosomes of different
phylogenetic domains in vivo while retaining its functional
characteristics. It is likely that this possibility will help
to study mechanisms of the various eukaryotic rRNA
decoding sites in the future and to test hypotheses built
upon X-ray structures. The construction of hybrid
ribosomes, as demonstrated in this study, should also
help characterizing the specificity of ribosomal inhibitors
already available and of future compounds to come.
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Supplementary Figure 1. Strategy for deletion of chromosomal rRNA operons. Broken 
lines indicate possible crossover sites between homologous sequences in the replacement 
vector (A) and the chromosomal target site (B). Following plasmid integration into the rrnB 
5’-flanking region (C), a second crossover event between the homologous 3’-flanking 
sequences resolves the chromosomal tandem repeat to the deletion of rrnB (D). Open 
arrows represent rRNA genes; P and T the promoter and termination sequences, 
respectively. Solid arrows indicate the open reading frames upstream and downstream of 
rrnB. Hatched rectangles represent antibiotic resistance cassettes, the stippled arrow the 
sacB gene. 
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Supplementary Figure 2. Chemical structures of the disubstituted 2-deoxystreptamine 
antibiotics used in this study. 
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Genetic analysis of interactions with eukaryotic
rRNA identify the mitoribosome as target
in aminoglycoside ototoxicity
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Aminoglycoside ototoxicity has been related to a surprisingly large
number of cellular structures and metabolic pathways. The finding
that patients with mutations in mitochondrial rRNA are hypersus-
ceptible to aminoglycoside-induced hearing loss has indicated a
possible role for mitochondrial protein synthesis. To study the
molecular interaction of aminoglycosides with eukaryotic ribo-
somes, we made use of the observation that the drug binding site
is a distinct domain defined by the small subunit rRNA, and
investigated drug susceptibility of bacterial hybrid ribosomes car-
rying various alleles of the eukaryotic decoding site. Compared to
hybrid ribosomes with the A site of human cytosolic ribosomes,
susceptibility of mitochondrial hybrid ribosomes to various ami-
noglycosides correlated with the relative cochleotoxicity of these
drugs. Sequence alterations that correspond to the mitochondrial
deafness mutations A1555G and C1494T increased drug-binding
and rendered the ribosomal decoding site hypersusceptible to
aminoglycoside-induced mistranslation and inhibition of protein
synthesis. Our results provide experimental support for aminogly-
coside-induced dysfunction of the mitochondrial ribosome. We
propose a pathogenic mechanism in which interference of amino-
glycosides with mitochondrial protein synthesis exacerbates the
drugs’ cochlear toxicity, playing a key role in sporadic dose-
dependent and genetically inherited, aminoglycoside-induced
deafness.
decoding  mitochondria  ribosomes  toxicity  translation
Low cost and high efficacy make aminoglycosides a commonchoice for treatment of serious infections caused by gram-
negative bacilli, including endocarditis, sepsis, pneumonia, py-
elonephritis, and multidrug-resistant tuberculosis (1). Unfortu-
nately, aminoglycosides are both nephrotoxic and ototoxic.
Although renal impairment is in general mild and reversible,
ototoxicity results from drug-induced apoptosis of cochlear and
vestibular hair cells and is irreversible (2, 3). Ototoxicity of
aminoglycoside antibiotics occurs both in a dose-dependent and
in an inherited idiosyncratic fashion. Despite attempts to limit
drug doses and to monitor blood levels carefully, measurable
signs of hearing loss are found in 20% of patients receiving
aminoglycosides (2). Familial cases of aminoglycoside-induced
deafness are maternally transmitted and linked to mutations in
mitochondrial DNA (mtDNA) (4–6).
The mechanisms by which aminoglycoside antibiotics exert
their toxic effects are controversial. A surprisingly large and
diverse number of effects have been associated with aminogly-
cosides. Aminoglycosides have been reported to affect DNA,
RNA, and protein synthesis; energy metabolism and ion trans-
port; and synthesis or degradation of prostaglandins, ganglio-
sides, mucopolysaccharides and lipids (2). In addition, it has
been hypothesized that aminoglycosides may form cochleotoxic
metabolites. Antioxidants apparently attenuate aminoglycoside-
induced hearing loss, pointing to a role of the mitochondrion, an
organelle involved in oxidation, as a target of ototoxic drugs (7,
8). Genetic analyses of individuals hypersensitive to aminogly-
cosides have identified mutations in mitochondrial rRNA. Tran-
sition mutations in the mitochondrial small ribosomal RNA
gene, namely A1555G and, less frequently C1494T, have been
identified as primary genetic traits in aminoglycoside-induced
deafness (4, 6, 9). A1555G and C1494T both map to the
aminoacyl-tRNA acceptor site (A site) of the small ribosomal
subunit. The bacterial A-site rRNA is target for aminoglycoside
antibiotics, which exert their antibacterial effect at the level of
the prokaryotic ribosome (10–13). Aminoglycosides affect pro-
tein synthesis by inducing codon misreading and by inhibiting
translocation of the tRNA-mRNA complex (14, 15). The basis
for aminoglycoside selectivity is presumably their preferential
binding to the bacterial as opposed to eukaryotic ribosomes (13,
16, 17).
The high copy number of mtDNA inmitochondria and the vast
number of mitochondria in a single cell have frustrated any
attempt of genetic manipulation of mitochondrial rRNA in lower
and higher eukaryotes. Model oligonucleotides designed to
mimic the drug-binding site have been used to investigate various
aspects of aminoglycoside-ribosome interaction (18–22). How-
ever, conclusions derived from the study of model A-site oligo-
nucleotides are compromised by several findings: (i) in contrast
to drug susceptibility of complete ribosomes, binding affinities of
aminoglycosides to prokaryotic decoding region constructs are
not very sensitive to mutations within the RNA-binding region
(23); (ii) in vivo drug susceptibilities of mutant ribosomes and in
vitro binding affinities using variants of model A-site oligonu-
cleotides may or may not correlate (24–26); (iii) the exquisite
specificity of aminoglycosides for the prokaryotic as opposed to
the eukaryotic cytosolic ribosome contrasts with the observation
that these drugs bind to eukaryotic decoding-site constructs with
approximately the same affinity as found for their prokaryotic
counterpart (23, 24); and (iv) while there is evidence that
mitochondrial ribosomes are susceptible to aminoglycosides (13,
27), oligonucleotides mimicking the mitochondrial A site do not
bind aminoglycosides to any significant extent (24, 28).
Using gene-shuffling experiments, we have previously re-
placed the A-site residues of helix 44 (H44) in bacterial 16S
rRNA with various eukaryotic homologues, demonstrating that
the A-site rRNA behaves as an autonomous domain, which can
be exchanged between different species for study of function (29,
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30). Replacement of a 34-nucleotide portion of bacterial 16S-
rRNA helix 44 with its human homologues resulted in rRNA-
decoding sites virtually identical to that in cytosolic and mito-
chondrial ribosomes. Here we used hybrid bacterial ribosomes
carrying distinct alleles of the mitochondrial decoding site to
study aminoglycoside susceptibility of wild-type and mutant
mitochondrial rRNA.
Results and Discussion
The in vivo activity of various 2-deoxystreptamine antibiotics
against isogenic Mycobacterium smegmatis strains carrying mi-
tochondrial-bacterial hybrid ribosomes was tested in minimal
inhibitory concentration (MIC) assays, which determine growth
inhibition at the whole-cell level. Compared to bacterial ribo-
somes, which were found to be unanimously susceptible to all
aminoglycosides tested, the hybrid ribosomes with a wild-type
mitochondrial H44 revealed a heterogeneous drug susceptibility
pattern, with MIC values ranging from 32 to 1,024 g/ml (Table
1). The ratio of MIC mitochondrial hybrid to MIC wild-type M.
smegmatis varied from 64-fold (gentamicin, amikacin) to 256-
fold (netilmicin, kanamycin), providing a relative measure of the
drug-target selectivity of different 2-deoxystreptamine antibiot-
ics. We next investigated recombinants where the bacterial H44
has been replaced by mitochondrial deafness alleles correspond-
ing to mtDNA mutations A1555G and C1494T. The resulting
mutant mitochondrial hybrid ribosomes differ from the wild-
type mitochondrial hybrid only in 16S rRNA residues 1490 and
1410; compare Fig. 1C to Fig. 1 D and E (bacterial 16S rRNA
residues are numbered according to Escherichia coli nomencla-
ture). The presence of the A1555G or the C1494T mutation
increased drug susceptibility of cells carrying the mitochondrial
hybrid ribosomes by 4- to 16-fold (see Table 1).
For a more detailed study of the mt A1555G and C1494T
alleles, we studied purified hybrid ribosomes in cell-free trans-
lation reactions. We first used an AUG(UUU)12-mRNA tem-
plate, as this message allows determination of drug-induced
inhibition of polypeptide synthesis and amino acid misincorpo-
ration. Dose-response curves of aminoglycoside-induced inhibi-
tion of phenylalanine incorporation were analyzed to define the
IC50 values of the individual 2-deoxystreptamines. Both the
A1555G and the C1494T genotypes were more susceptible to
aminoglycoside antibiotics than the wild-type mitochondrial
decoding site, as indicated by the finding that significantly less
drug concentrations were required to inhibit AUG(UUU)12
mRNA-driven polyPhe synthesis [see Fig. 2A, Table 2, and
supporting information (SI) Fig. S1].
Aminoglycosides are known to affect the translational fidelity
of ribosomes by inducing misreading of the genetic code (14).
For study of aminoglycoside-induced mistranslation we used the
AUG(UUU)12-driven polypeptide synthesis assay to determine
Table 1. Minimal inhibitory concentrations (g/ml) of aminoglycoside antibiotics
Aminoglycoside
A-site rRNA
Bacteriala
Mitochondrial (mt)
hybrid
mt A1555G
hybrid
mt C1494T
hybrid
Neomycin B 0.5 16–32 8 8
Paromomycin 1  1,024 256–512 256–512
Kanamycin A 1 256–512 16–32 16
Tobramycin 1 128 16 16
Amikacin 0.5 32–64 2–4 2–4
Gentamicin 1 64–128 16–32 16–32
Netilmicin 2 512–1024 64 64–128
aM. smegmatis wild-type rRNA
Fig. 1. Secondary structure of rRNA helix 44 in the ribosomal decoding site. (A) Decoding site of M. smegmatis wild-type ribosomes; rRNA nucleotides are
numbered according to the bacterial nomenclature (i.e., homologous E. coli 16S rRNA positions). (B) Decoding site of human mitochondrial ribosomes; rRNA
residues are numbered according to the mitochondrial nomenclature. (C–E) Mitochondrial decoding sites within human-bacterial hybrid ribosomes: wild type
sequence (C) and deafness-associated alterations adenine to guanine at position 1490 (corresponding to mitochondrial mutation A1555G) (D); cytosine to uracil
mutation at position 1410 (corresponding to mitochondrial mutation C1494T) (E). Nucleotide positions depicted in blue represent residues that are specific for
human rRNA; nucleotide positions in red highlight the pathogenic mutations; the transplanted helix is boxed. (F) Decoding site of the M. smegmatis G1491C
mutant.
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the relative amount of near-cognate leucine incorporation com-
pared to incorporation of the cognate amino acid phenylalanine
in the presence of various concentrations of gentamicin. Relative
incorporation of [3H]-labeled leucine versus [14C]-labeled phe-
nylalanine was determined and plotted against gentamicin con-
centration. Introduction of the A1555G and C1494T alteration
rendered the mitochondrial hybrid ribosomes highly susceptible
to aminoglycoside-induced misreading (Fig. 2B; see also Fig.
S2). In quantitative terms, the amount of gentamicin-induced
misreading (calculated as leucine per phenylalanine incorpora-
tion) in A1555G and C1494T mutant hybrid ribosomes was up
to 1.75 leucine per phenylalanine, as compared to a maximum of
0.2 leucine per phenylalanine for hybrid ribosomes with a
wild-type mitochondrial decoding site.
To study the effect of aminoglycoside antibiotics on translation
of a more natural mRNA template, we tested wild-type andmutant
mitochondrial hybrid ribosomes in a cell-free luciferase synthesis
assay. As depicted in Fig. 2C, Table 3, and Fig. S3, the allele- and
drug-specific inhibition of luciferase synthesis essentially correlated
with the results of the MIC and AUG(UUU)12 assays. Drug-
mediated inhibition of luciferase synthesis was significantly in-
creased in A1555G and C1494T mutant ribosomes.
The basis for the selectivity of aminoglycosides is presumably
their preferential binding to bacterial as opposed to eukaryotic
ribosomes (10, 13, 16, 17). In particular, 16S rRNA nucleotides
1408, 1409, and 1491 of helix 44 have been shown to be critical
for drug-binding by forming direct contacts with ring I of the
2-deoxystreptamines (12, 13, 16, 17, 26, 31–38) (see Fig. S4 for
the chemical structures of aminoglycosides used in this study). In
the absence of X-ray structures for aminoglycosides complexed
to the mitochondrial ribosome, we can rationalize our findings
on data invoked from the study of bacterial ribosome-drug
complexes (12, 39). The rRNA secondary structure of the drug
binding site in mitochondrial A1555G and C1494T mutant
ribosomes resembles that of bacterial ribosomes with a G1491C
alteration in that the C1409-C1491 opposition is accompanied by
a 1410–1490 Watson–Crick pair (see Fig. 1). The bacterial
G1491C ribosome shows a drug-susceptibility phenotype that is
virtually superimposable on that found for the mitochondrial
deafness alleles (see Table S1 for comparison). To determine
whether the affinity of aminoglycosides to mutant mitochondrial
decoding sites corresponds to that of the bacterial G1491C
decoding site, we probed gentamicin binding by chemical foot-
printing experiments. Bacterial wild-type ribosomes showed
drug-mediated protection from dimethyl sulfate (DMS) modi-
fication at G1405 (N-7), which is in good agreement with
previous reports on aminoglycoside protection in bacterial 16S
rRNA (34). Wild-type mitochondrial hybrid ribosomes showed
little protection, while mutant mitochondrial A1555G and
C1494T hybrid ribosomes showed a concentration-dependent
protection of G1405 that resembles the dose-response curve
observed with bacterial G1491C ribosomes (Fig. 3). Thus, bind-
ing of aminoglycosides to ribosomes with an adenine at 16S
rRNA position 1408, appears to be mainly determined by the
structural geometry of base pairs 1409–1491 and 1410–1490.
When studying drug-induced miscoding, we found that the
decoding accuracy of bacterial G1491C ribosomes is barely
affected by aminoglycoside antibiotics. In absolute terms and in
contrast to the mitochondrial A1555G and C1494T deafness
mutants, the bacterial G1491C ribosomes showed little drug-
Fig. 2. Aminoglycoside susceptibility of mutant and wild-type mitochondrial hybrid ribosomes. Dose-response curves of wild-type mitochondrial (red squares),
mutant A1555G (green triangles), and mutant C1494T (blue inverted triangles) hybrid ribosomes; bacterial ribosomes (black circles) are included for comparison.
(A) Gentamicin-induced inhibition of [14C]-phenylalanine incorporation (n  3;  SD.). The 100% value corresponds to 25 to 30 pmol Phe incorporation.
Corresponding IC50 values of gentamicin and selected aminoglycoside antibiotics are presented in Table 2. (B) Gentamicin-induced increase in misincorporation
of the near-cognate [3H]-leucine relative to the drug-free control (n 3; SD.). (C) Gentamicin-induced inhibition of luciferase synthesis relative to the drug-free
control (n  3;  SD.). Corresponding IC50 values for gentamicin and selected aminoglycoside antibiotics are presented in Table 3.
Table 2. Aminoglycoside-induced inhibition of AUG(UUU)12-driven phenylalanine
incorporation (IC50, M)
Aminoglycoside
A-site rRNA
Bacteriala
Mitochondrial (mt)
hybrid
mt A1555G
hybrid
mt C1494T
hybrid
Neomycin B 0.2  0.0 209  61 3.1  0.3 3.7  0.7
Paromomycin 0.7  0.1  500 124  35 116  20
Kanamycin A 1.2  0.2  500 20  2 95  29
Tobramycin 0.7  0.1  500 15  3 70  23
Amikacin 0.8  0.1  500 7.1  0.8 13  3
Gentamicin 1.3  0.2  500 13  2 62  16
Netilmicin 1.2  0.3  500 71  10 331  84
IC50 values represent the drug concentrations in M that are required to inhibit AUG(UUU)12-driven phenyl-
alanine incorporation to half-maximal extent. A representative graph showing phenylalanine incorporation
plotted against gentamicin concentration is shown in Fig. 2A.
aM. smegmatis wild-type rRNA
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induced misreading (see Fig. S2). The bacterial G1491C mutant
and the hybrid deafness ribosomes differ primarily in 16S rRNA
residues 1413 to 1415 and 1485 to 1487, which form the lower
stem of helix 44 (see Fig. 1). At the structural level, helix 44
interacts with helix 27. By modeling, nucleotide alterations in the
lower stem of H44 have been suggested to affect this interaction
and the relative movement between these two helices as part of
the conformational change required in decoding (30). Appar-
ently, the nature of the lower stem plays an important role in
both spontaneous and drug-aggravated miscoding and deter-
mines the translational accuracy of the mutant decoding sites.
Thus, susceptibility of A1555G and C1494T deafness mitoribo-
somes is the result of two mechanisms, which act in concert:
increased drug binding to its target and excessive aggravation of
the mutants’ inherent deficiency in ribosomal accuracy.
Several lines of evidence link aminoglycoside ototoxicity to the
mitochondrial ribosome: (i) mitochondrial ribosomes are struc-
turally more similar to their prokaryotic ancestor than to the
eukaryotic cytosolic homologues; (ii) compared to cytosolic
ribosomes, the mitochondrial ribosomes of higher eukaryotes
exhibit a remarkable degree of aminoglycoside susceptibility
(27) [see Table S2, which compares the drug susceptibility of
hybrid bacterial ribosomes with the A site (H44) of human
cytosolic ribosomes to that of hybrid ribosomes with the mitochon-
drial decoding site]; and (iii) idiosyncratic drug susceptibility is
associated with genetic predisposition, in particular mutations in
mtDNA: 20 to 40% of patients with aminoglycoside-induced
ototoxicity either carry the A1555G or the C1494T mutation in
the 12S rRNA gene (6, 40).
To further assess whether aminoglycoside-induced ototoxicity
is a result of the drugs’ anti-mitoribosomal activity, we compared
the potencies of a series of aminoglycosides to inhibit mitoribo-
some function with their relative cochleotoxicity in humans (41).
The correlation between these two measures (Fig. 4) is consis-
tent with the hypothesis that aminoglycoside-induced cochleo-
toxicity relates to the drugs’ activity against mitochondrial
ribosomes. Further evidence for this hypothesis is provided by
our finding that netilmicin, which displays the least cochlear
toxicity of the clinical aminoglycosides (reviewed in ref. 42), is
significantly less active against hybrid mitochondrial ribosomes
than gentamicin, tobramycin, or amikacin.
In summary, we provide experimental evidence for a mech-
anistic linkage between the mitochondrial A1555G and C1494T
mutations and hypersusceptibility to aminoglycosides, although
the exquisite tissue-specific action of aminoglycoside toxicity
(that is, ototoxicity) is likely to involve additional factors (e.g.,
reactive oxygen species, drug uptake, or polyamine-like activa-
tion of NMDA receptors) (2, 43). Our results provide experi-
mental support for aminoglycoside-induced dysfunction of the
mitochondrial ribosome. We propose a pathogenic mechanism,
in which interference of aminoglycosides with mitochondrial
protein synthesis exacerbates the drugs’ cochlear toxicity, play-
ing a key role in sporadic dose-dependent and genetically
inherited, aminoglycoside-induced deafness. Based upon our
experiments, we suggest a scenario of aminoglycoside hearing
Table 3. Aminoglycoside-induced inhibition of luciferase synthesis (IC50, M)
Aminoglycoside
A-site rRNA
Bacteriala
Mitochondrial (mt)
hybrid
mt A1555G
hybrid
mt C1494T
hybrid
Neamine 1.4 131 32 35
Neomycin B 0.04 0.7 0.5 0.4
Paromomycin 0.03 33 2.4 3.1
Kanamycin A 0.05 15.7 1.2 1.1
Tobramycin 0.02 7.8 0.8 0.9
Amikacin 0.02 7.0 0.4 0.6
Gentamicin 0.03 5.7 0.6 0.7
Netilmicin 0.05 17.6 0.8 2.6
IC50 values represent the drug concentrations in M that are required to inhibit synthesis of functional firefly
luciferase to 50%. Relative luciferase activity plotted against aminoglycoside concentration is shown in Fig. 2C.
aM. smegmatis wild-type rRNA
Fig. 3. Chemical footprints of gentamicin binding to wild-type and mutant
mitochondrial decoding sites in comparison to bacterial wild-type and G1491C
ribosomes. (A) Gentamicin-dependent protection of G1405 in wild-type mi-
tochondrial (red squares), mutant mt A1555G (green triangles), mutant mt
C1494T (blue inverted triangles), and bacterial G1491C (purple diamonds)
decoding sites; wild-type bacterial ribosomes (black circles) are included for
comparison. (B) Corresponding footprinting blots showing primer extensions
starting with U1420. i, bacterial wild type; ii, mt wild type; iii, mt A1555G; iv,
mt C1494T; v, bacterial G1491C.
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loss, which is initiated by mitoribosomal misreading, subse-
quently via activation of downstream signaling pathways, such as
MAPK and JNK (44, 45), misreading results in hair cell death
through apoptosis.
Materials and Methods
Construction of Mutant Strains with Hybrid Ribosomes. The recently described
M. smegmatis mc2 155 SmS rrnB (38) was used for all genetic manipulations.
Site-directed mutagenesis of its single rRNA operon was done by PCR mu-
tagenesis using hybrid rDNA oligonucleotides comprising the wild-type or
mutant mitochondrial helix 44 decoding-site sequence. The resulting hybrid
gene fragment was cloned into an integration-proficient plasmid used to
transformM. smegmatisrrnB. Transformants were selected on LB agar plates
containing 20 g/ml paromomycin for gene replacement by homologous
recombination. Resulting recombinant M. smegmatis cells had the central
34-nucleotide part of the bacterial H44 replaced by its mitochondrial coun-
terpart. Successful replacement of the bacterial decoding-site sequence with
the mitochondrial sequence was controlled by sequence analysis of the chro-
mosomal rrnA locus.
Minimal Inhibitory Concentration Assays. Minimal inhibitory concentrations of
neomycin B, paromomycin, kanamycin A, tobramycin, amikacin, gentamicin,
netilmicin (all Sigma), and neamine were determined by broth microdilution
assays as described previously (46). Neamine was a kind gift of Andrea Vasella,
ETH Zurich. The gentamicin used in this study is a mixture of gentamicin C1,
gentamicin C1a, and gentamicin C2 in a 45:35:30 ratio.
Isolation and Purification of Ribosomes. Ribosomes were purified from bacte-
rial cell pellets as described previously (30). In brief, ribosome particles were
isolated by successive centrifugations and fractionated by sucrose gradient
(10–40%) centrifugation. The 70S ribosome-enriched fraction was pelleted,
resuspended in association buffer, incubated for 30 min at 4 °C, dispensed into
aliquots, and stored at 80 °C following shock freezing in liquid nitrogen.
Ribosome concentrations of 70S were determined by absorption measure-
ments on the basis of 23 pmol ribosomes perA260 unit. Integrity and functional
activity of purified 70S ribosomes was determined by analytical ultra-
centrifugation and by assessing their capacity to form initiation complexes, as
described previously (29).
Cell-free AUG(UUU)12 Translation Assays. Cell-free translation reactions were
done as described previously (30). A reaction mixture containing M. smegma-
tis tRNAbulk, amino acids, S100 extract, energy mix, pyruvate kinase, and
polyamines was preincubated with 30 M [14C]-phenylalanine (110 mCi/
mmol) and/or 30 M [3H]-leucine (500 mCi/mmol) at 37 °C for 15 min. The
translation reaction was started by addition of ribosomes to a final concen-
tration of 0.25 M, AUG(UUU)12-mRNA (5-GCGGCAAGGAGGUAAAUA AUG
(UUU)12 UAA GCAGG-3, obtained from Dharmacon) to 1 M, and aminogly-
coside antibiotics in serial dilutions. Following incubation for 60 min at 37 °C,
the reaction was stopped by addition of KOH, precipitated polypeptides were
collected on filters, and [14C]-phenylalanine or [3H]-leucine were quantified.
Background values for Phe and Leu incorporation were 0.4 to 0.5 pmol at time
zero; the background was not subtracted from the experimental values
determined.
Cell-Free Luciferase Translation Assays. Purified 70S hybrid ribosomes were
used in a coupled transcription-translation reaction as described previously
(29). The reaction mixture was incubated for 60 min at 37 °C, stopped on ice,
and luciferase assay substrate (Promega) was added. Functional protein was
quantified by measuring bioluminescence in a luminometer (Bio-Tek instru-
ments, FLx800).
Footprinting Analyses. DMS modification of 70S ribosomes (20 pmol) was per-
formedin100lbuffercontaining80mMpotassiumcacodylate (pH6.5),100mM
ammonium chloride, 20 mM magnesium chloride, 1 mM DTT, and 0.5 mM EDTA.
Following ribosome activation for 15 min at 37 °C, gentamicin was added and the
reaction mixture was incubated for another 15 min before addition of DMS (6l,
1:10 inethanol).Followinga30-minincubationat37 °C, thereactionwasstopped
by addition of 100 l DMS Stop solution (50 mM Tris, pH 7.5, 300 mM sodium
chloride, 1% SDS, 200 mM -mercaptoethanol). Ribosomes were precipitated
with ethanol, pelleted, resuspended in 200 l 50 mM Tris pH 8, 0.5% SDS, and
extracted with phenol/chloroform. DMS-modified RNA was precipitated with
ethanol and sodium borohydride reduction and aniline-induced strand scission
was performed as described previously (47). Primer extension of 16S rRNA was
performed as described (48), using DNA oligonucleotides complementary to
16S-rRNA nucleotides 1445 to 1421. Air-dried gels were scanned and quantified
using the STORM PhosphorImaging System with ImageQuant 5.2 Software (Am-
ersham Bioscience).
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Fig. S1. Aminoglycoside susceptibility of bacterial hybrid ribosomes in AUG(UUU)12-directed polypeptide synthesis. Dose-response curves of bacterial (black
circles), mitochondrial (red squares), mutant A1555G (green triangles), andmutant C1494T (blue inverted triangles) hybrid ribosomes. Corresponding IC50 values
are given in Table 2.
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Fig. S2. Aminoglycoside-inducedmiscoding relative to a drug-free control in aM. smegmatisG1491Cmutant in comparison tomutantmitochondrial decoding
sites. Dose-response curves ofM. smegmatisG1491C (purple diamonds),mitochondrial (red squares),mutantA1555G (green triangles), andmutant C1494T (blue
inverted triangles) hybrid ribosomes. Bacterial wild-type ribosomes (black circles) are included for comparison.
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Fig. S3. Aminoglycoside-induced inhibition of luciferase synthesis. Dose-response curves of bacterial (black circles), mitochondrial (red squares), mutant
A1555G (green triangles), and mutant C1494T (blue inverted triangles) hybrid ribosomes. Corresponding IC50 values are given in Table 3.
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Fig. S4. Chemical structures of 2-deoxystreptamine antibiotics used in this study.
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Table S1. Minimal inhibitory concentrations (g/ml) against M. smegmatis G1491C mutant in comparison to mutant mitochondrial
hybrids
A-site rRNA
M. smegmatis Mitochondrial (mt) hybrid mt A1555G hybrid mt C1494T hybrid M. smegmatis G1491C
Neomycin B 0.5 16–32 8 8 16
Paromomycin 1  1,024 256–512 256–512 512
Kanamycin A 1 256–512 16–32 16 16–32
Tobramycin 1 128 16 16 16
Amikacin 0.5 32–64 2–4 2–4 4
Gentamicin 1 64–128 16–32 16–32 16–32
Netilmicin 2 512–1,024 64 64–128 128
Hobbie et al. www.pnas.org/cgi/content/short/0811258106 5 of 6
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Table S2. Aminoglycoside susceptibility of the mitochondrial
versus the cytosolic decoding site
MIC (g/ml)
Mitochondrial hybrid Cytosolic hybrid
Neomycin B 16–32  1,024
Kanamycin A 256–512  1,024
Tobramycin 128 1,024
Amikacin 32–64 512–1,024
Gentamicin 64–128  1,024
Netilmicin 512–1,024  1,024
Hobbie et al. www.pnas.org/cgi/content/short/0811258106 6 of 6
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Abstract 
 
Recent studies have suggested that ribosomal protein S12 modulates 16S rRNA 
function and susceptibility to 2-deoxystreptamine aminoglycosides. To study whether 
the non-restrictive K42R mutation in RpsL affects 2-deoxystreptamine susceptibility in 
Mycobacterium smegmatis, we studied the drug susceptibility pattern of various 
mutants with genetic alterations in the 16S rRNA decoding A-site in the context of 
wild-type and mutant protein S12. RpsL K42R substitution was found not to affect the 
drug resistance pattern associated with mutational alterations in 16S rRNA H44. 
 
Introduction 
 
Ribosomal protein S12 is a critical component of the A-site of the 30S ribosomal subunit and 
is involved in both tRNA selection and resistance to streptomycin [1,2]. Mutations in rpsL 
coding for ribosomal protein S12 are known to affect ribosomal accuracy to various extents, 
resulting in what is characterized as error-restrictive or non-restrictive S12 alterations [3]. 
Streptomycin inhibits protein synthesis and makes ribosomes error prone by affecting initial 
tRNA selection and proof-reading [4]. Mutations in S12 confer streptomycin resistance by 
preventing streptomycin binding and/or conferring ribosomal hyperaccuracy; a strongly 
hyperaccurate phenotype may even manifest as streptomycin-dependence [2]. Various 
substitutions at positions 42 and 87 are associated with streptomycin resistance. In 
particular, mutations Lys42 → Arg, Ala or Thr promote high levels of streptomycin resistance; 
among those Lys42Arg has a non-restrictive phenotype [3], whereas Lys42Ala and Lys42Thr 
are strongly error-restrictive [3,5,6]. S12 substitutions Lys87 → Gln or Gly confer different 
degrees of streptomycin resistance [7,8]. The homologous mammalian ribosomal proteins 
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carry Gln-87 (human mitochondrial ribosomes) or Gly-87 (human cytoplasmic ribosomes) in 
part accounting for the drugs’ prokaryotic specificity [7].  
More recently it has been suggested that ribosomal protein S12 modulates 16S-rRNA 
function and susceptibility to 2-deoxystreptamine aminoglycosides [5,6]. 2-deoxystreptamine 
aminoglycosides are composed of a common core, termed neamine, in which position 4 of a 
2-deoxystreptamine ring (ring II) is attached to a glycopyranosyl ring (ring I). Additional 
sugars are attached to position 5 or 6 of the 2-deoxystreptamine moiety to give rise to 4,5- or 
4,6- aminoglycosides (see Supplementary Data Fig. S1). In 4,5- aminoglycosides, the core is 
further substituted by one (ribostamycin), two (neomycin, paromomycin) or three 
(lividomycin) additional sugars attached to position 5 of ring II, whereas in 4,6- 
aminoglycosides (gentamicin, tobramycin, kanamycin, etc.) the core is further substituted by 
one additional sugar attached to position 6 of ring II. The drug binding pocket for these 
compounds consists of an internal loop of 16S-rRNA helix 44 – the decoding A-site of the 
ribosome [9]. We have previously performed extensive genetic studies of 16S-rRNA helix 44 
in Mycobacterium smegmatis to address the role of individual rRNA residues in drug binding 
(reviewed in [10]). These studies have been conducted mainly in the genetic background of a 
non-restrictive K42R mutation in ribosomal protein S12 [10-16]. The K42R mutation confers 
high-level resistance to streptomycin and was used as counter-selectable marker in strain 
construction [15]. The recent reports on the interplay of S12 on 16S rRNA function and 
susceptibility to 2-deoxystreptamine aminoglycosides prompted us to study in detail the role, 
if any, between RpsL K42R and mutational alterations in 16S-rRNA helix 44 conferring 
resistance to 2-deoxystreptamines. We find that the non-restrictive RpsL K42R mutation 
does not affect the 2-deoxystreptamine susceptibility of various rRNA mutations in 
M. smegmatis H44.  
 
Results and Discussion 
 
Generation of M. smegmatis strains with mutations in S12 and 16S rRNA 
M. smegmatis was the first eubacterial model organism that was made single rRNA allelic by 
means of deletion mutagenesis and that allowed for genetic studies of its ribosomal RNA 
[16]. As a gram-positive mesophilic bacterium, M. smegmatis is susceptible to a number of 
ribosomal antibiotics and sets itself apart from other model organisms by being a close 
representative of clinically relevant pathogenic bacteria. Early genetic studies on 
susceptibility to 2-deoxystreptamine aminoglycoside antibiotics relied on M. smegmatis 
strains with a K42R mutation in ribosomal protein S12 [10-16]. To substantiate the results 
and conclusions drawn from these early studies, we constructed a comprehensive set of 
M. smegmatis rRNA mutants in the context of both a wild-type and a mutant S12 (Table S1). 
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The set of 16S rRNA mutants includes alterations of positions 1408 (A1408G), 1491 
(G1491C; G1491U; G1491A) and 1409 (C1409U; C1409G). 
 
Aminoglycoside susceptibility of M. smegmatis mutants 
Aminoglycoside susceptibility of the mutant strains was determined by minimal inhibitory 
concentration (MIC) assays. Representatives for each of the two disubstituted 2-
deoxystreptamine subclasses were included: the 4,5-disubstituted 2-deoxystreptamines 
paromomycin and neomycin and the 4,6-disubstituted 2-deoxystreptamines gentamicin,  
tobramycin and kanamycin. The results are presented in Table 1.  
 
 
Table 1. Drug susceptibility of M. smegmatis 16S rRNA mutants: wild-type S12 versus K42R 
 
16S rRNA residues S12 MIC (μg/mL) Reference 
1408 1409–1491  Pm Nm Gm Tb Km  
         
A C≡G wt 1 0.5 1 1 0.5-1 this study 
A C≡G K42R 1 1 1 1 0.5-1 [12] 
G C≡G wt 64 > 1024 > 1024 > 1024 > 1024 this study 
G C≡G K42R 64 ≥ 1024 > 1024 > 1024 > 1024 [12] 
A C • C wt 512 16 16-32 16 16-32 this study 
A C • C K42R 512 16-32 16-32 16-32 16-32 [12] 
A C • U wt 512-1024 8-16 32-64 64 64-128 this study 
A C • U K42R 512 8-16 32 32-64 128 [12] 
A C • A wt 32-64 2 2 2 1-2 this study 
A C • A K42R 32 4 2 4 2 [12] 
A U · G wt 4-8 0.5-1 8 8-16 8-16 this study 
A U · G K42R 4-8 1 8-16 8-16 16 [12] 
A G • G wt 32-64 4-8 1-2 8-16 32-64 this study 
A G • G K42R 16-32 4 2-4 8-16 16-32 [12] 
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Pm, paromomycin; Nm, neomycin; Gm, gentamicin;  Tb, tobramycin; Km, kanamycin A. 
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Among all A-site mutations that confer aminoglycoside resistance, the A1408G mutation is 
the most significant. In M. smegmatis the A1408G mutation confers moderate resistance to 
paromomycin (6′ OH) but high level resistance to 2-deoxystreptamine aminoglycosides with 
an amino group at the 6′ position of ring I. A key element in drug binding is the pseudo base-
pair interaction between the aminoglycosides’ ring I and A 1408 [13,17,18]. In case of an 
adenine, the oxygen of ring I accepts a hydrogen bond from the N6 of A1408, and the amino 
or hydroxyl group at position 6′ donates a hydrogen bond to the N1 of adenine, accounting 
for two direct hydrogen bonds between ring I and A1408 (Fig. 1). In case of a 1408 guanine, 
the 6′ amino group of ring I can no longer form an H bond with the Watson-Crick edge of 
residue 1408. Additionally, the positive charge of the 6′ amino group creates repulsion 
against the N1 and N2 amino groups of guanine. As a consequence, the A to G mutation 
prevents aminoglycoside binding by precluding the proper insertion of ring I into the binding 
site. In contrast, a 6′- hydroxyl group, as in paromomycin could still become an acceptor of 
an H bond from N1 or N2 of the guanine, although the resulting pseudo base pair does not 
appear to promote optimal insertion of ring I, as indicated by decreased ribosomal drug 
susceptibility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Stacking interaction of ring I with G1491 and pseudo-base pairing of ring I 
with A1408. The hydrogen bonding contacts between ring I and A1408 are indicated by 
black broken lines 
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The Watson–Crick base pair C1409–G1491 forms the base of the drug binding pocket. In the 
crystal structures [17,18], G1491 provides a stacking interaction with ring I of the 
aminoglycosides, thereby stabilizing the pseudo base-pair interaction of ring I with A1408 
(Fig. 1). Among all mutations investigated affecting base-pair interaction C1409-G1491, the 
transversion mutations G1491C and G1491U (resulting in pyrimidine-pyrimidine oppositions) 
confer the highest level of resistance, in particular to paromomycin. Presumably, a 
pyrimidine-pyrimidine opposition provides a conformation that sterically hinders the correct 
positioning of ring I. A pyrimidine-purine opposition is retained following transition of G1491 
to A resulting in 1409C–A1491. This mutational alteration apparently interferes less with drug 
binding, as indicated by the mutants’ drug susceptibility pattern. The C1409U mutant shows 
little resistance to aminoglycosides. Nucleotide C1409 is not involved directly in drug binding, 
but is responsible for the correct orientation of nucleotide 1491, as 1409 and 1491 form a 
Watson–Crick base pair. The mutant wobble-base pair interaction 1409U–G1491 is likely to 
show conformational characteristics resembling those of the wild-type C–G. Mutation 
C1409G leads to a purine–purine opposition 1409G–G1491 in which the exact nature of 
interaction is difficult to predict. Surprisingly, the resistance levels conferred by this mutation 
are low to moderate. In general, sequence alterations in C1409-G1491 while mostly affecting 
the 6′ OH paromomycin do not discriminate between 4,5- and 4,6-aminoglycosides [10]. This 
is in agreement with the structural observation that ring I binds in the same orientation 
irrespective of the substituents at the 2-deoxystreptamine ring [18]. 
Strains with mutations in 16S rRNA residues 1408, 1409 and 1491 show a mutation-specific 
drug susceptibility pattern that was independent of the amino acid residue 42 in ribosomal 
protein S12 (wt vs K42R, see Table 1) and that corresponded to previously published data 
[12]. These results demonstrate that the K42R mutation in ribosomal protein S12 does not 
affect the susceptibility of M. smegmatis H44 mutants to 2-deoxystreptamines. Notably, this 
finding is not fully congruent with a previous finding in E. coli where K42R (the rpsL226 
allele) reportedly modulated the level of paromomycin resistance of a G1491U mutant [19].  
To study whether the different findings reported for  E. coli are due to phylogenetic 
differences in the decoding-site rRNA, we constructed M. smegmatis with a proteobacteria-
like helix 44 (Fig. 2). M. smegmatis and E. coli differ in 16S rRNA residues 1410-1490 and 
1411-1489: 1410-1490 G-C (M. smegmatis) versus A-U (E. coli), 1411-1489 U-A (M. 
smegmatis) versus C-G (E. coli). We found that the various H44 mutations (A1408G, 
G1491A, G1491C, G1491U)  resulted in identical drug susceptibility patterns regardless of a 
mycobacterial and proteobacterial H44 sequence context at residues 1410-1490 and 1411-
1489 (data not shown).  
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Figure 2. Secondary structure of 16S rRNA helix 44 in the ribosomal decoding site. (A) 
Decoding site of E. coli wild-type (Proteobacteria). Four nucleotide positions depicted in 
green represent residues that are specific for E. coli 16S rRNA. (B) Decoding site of 
M. smegmatis wild-type (Mycobacteria) (C) Decoding site of M. smegmatis mutagenised to 
correspond to the polymorphism observed in E. coli i.e., Eco4.  
 
Structural analysis of K42 mutations 
Crystal structures of streptomycin bound to the small ribosomal subunit of T. thermophilus 
[17] have revealed two direct hydrogen bonds between streptomycin and the lysine residue 
42 of ribosomal protein S12 (Fig. 3A, 3B). K42 forms an additional contact to the phosphate 
backbone of 16S-rRNA helix 27 (H27) via a salt bridge to the phosphate group of residue 
A913. Superimposition of the K42R substitution disrupts the hydrogen bonding to 
streptomycin (Fig. 3C), accounting for the streptomycin resistance of K42R mutants. 
However, amino-acid substitution K42R leaves the salt bridge to H27 intact (Fig. 3C). Thus, 
the general structure of the A-site remains intact and rate and fidelity of translation remains 
unaffected [17]. This is in agreement with the observation that K42R is the only known 
mutation in S12 that confers streptomycin resistance but at the same time does not result in 
a hyper-accurate (i.e. restrictive) phenotype [3]. 
In contrast to K42R, mutations K42A or K42T disrupt the salt bridge to H27 (Fig. 3D, 3E). 
This mostly accounts for the restrictive phenotype of these mutations [17]. While K42A does 
not interfere with the binding of paromomycin directly [5], the hyperaccurate phenotype of the 
variant K42A ribosome in part functionally antagonizes aminoglycoside-induced misreading. 
Thus, these ribosomes show paromomycin-induced misreading only at much higher drug 
concentrations compared to wild-type [5]. 
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Figure 3. Three-dimensional crystal structure of T. thermophilus ribosomal decoding 
A-site with bound paromomycin and streptomycin. (A) General view of the A-site. 
Amino-acid residues of S12 (green) are shown labelled according to atoms: carbon – green, 
nitrogen – blue, oxygen – red. 16S rRNA helices are indicated as follows: H44 strand I (pink), 
H44 strand II (magenta), H27 (violet), H18 (orange). Streptomycin (light blue) and 
paromomycin (yellow). (B) Close up of wild type K42. Hydrogen bonds to streptomycin (black 
dotted lines) and salt bridge to A913 (red dotted line) are shown. (C) Close up of mutant 
K42R. Salt bridge (red dotted line) is shown. (D) Close up of mutant K42A (E) Close up of 
mutant K42T. (Protein Data Bank, 1FJG.pdb) 
 
Conclusions  
Our data demonstrate that K42R in ribosomal protein S12 does not affect resistance to 2-
deoxystreptamine aminoglycosides as conferred by 16S-rRNA mutations in H44, and that 
S12 most likely plays little role in the species-specific pattern of susceptibility to 2-
deoxystreptamines. This conclusion is supported by the observation that mutations 
G1645A/A1754G in S. cerevisiae 18S rRNA (homologous to E. coli residue A1408/G1491) 
reversed the natural resistance of yeast cytoplasmic ribosomes, i.e, increased the 
susceptibility to aminoglycosides from completely resistant (MIC > 5000 µg/ml) up to highly 
susceptible (MIC about 3 µg/ml). These levels of drug susceptibility are similar to those found 
in drug susceptible E. coli (MIC about 2.5-5 µg/ml) [20]. Thus, irrespective of ribosomal 
protein S12 (S. cerevisiae or E. coli), susceptibility to 2-deoxystreptamines is apparently 
determined by the nucleotide residues in small-subunit rRNA’s drug binding pocket. This 
finding contrasts with the view of a universal interrelation between S12, base pair 1409-1491 
and 2-deoxystreptamine susceptibility. Instead, it suggests that functional interactions 
between S12 and the 2-deoxystreptamine binding site are limited to certain bacterial genera 
and/or specific rpsL mutations. Interaction of S12 and 2-deoxystreptamine aminoglycosides 
apparently is not at the level of drug binding, but provoked by interference of two opposite 
effects on translation fidelity induced by error-restrictive rpsL mutations and misreading-
inducing aminoglycoside antibiotics. As a result, this interplay is limited to S12 amino acid 
substitutions which confer a hyperaccurate phenotype and thus are functional antagonists of 
drug-induced misreading. 
 
Materials and Methods 
 
Strains used in this study 
A single rRNA allelic strain M. smegmatis ∆rrnB (SZ380) was generated by unmarked 
deletion mutagenesis of the rrnB operon in M. smegmatis mc2155. A suicide vector pH022 
containing two DNA fragments flanking the rrnB operon (generated by PCR), a selectable 
marker (GmR) and counter-selectable marker sacB (both outside the rrnB DNA fragments), 
was transformed into M. smegmatis mc2155. A single rRNA allelic derivative was obtained by 
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a two-step selection procedure: selection of transformants on agar plates containing 
gentamicin followed by a counter-selection step on agar plates with sucrose. Deletion of rrnB 
was confirmed by Southern blot analysis and partial sequencing.  
Mutagenesis of the H44 decoding-site RNA was performed in strain M. smegmatis ∆rrnB 
(SZ0380) and in strain M. smegmatis ∆rrnB rpsL K42R (SZ0004) [12]. rRNA mutations were 
generated by PCR, cloned into vector pMIH-rrnB and introduced into the 16S rRNA A-site of 
the single rRNA allelic strain SZ0380 by RecA-mediated homologous recombination as 
described [12]. For a list of strains and plasmids see Tables S1 and S2 in supplementary 
data. 
Minimal inhibitory concentration (MIC) assay 
Drug susceptibility was studied by determining Minimal Inhibitory Concentrations (MIC). MIC 
tests were performed in a microtiter plate format as described [12]. In brief, freshly grown 
M. smegmatis cultures were resuspended in LB broth supplemented with 0.05% of Tween 
80, diluted to an absorbance at 600 nm of 0.025 and incubated in the presence of 2-fold 
serial dilutions of 2-deoxystreptamine aminoglycosides. After incubation at 37°C for 72 h, the 
MIC was recorded as the lowest concentration of drug inhibiting visible growth. 
 
Structural modelling  
PyMol (DeLano Scientific) was used to render the structure of the A-site of 30S ribosomal 
subunit from T.  thermophilus (Protein Data Bank, 1FJG.pdb) [21] 
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Figure S1. Chemical structures of disubstituted 2-deoxystreptamine antibiotics used 
in this study. 
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Table S1. Strains used in this study 
 
M. smegmatis strain Parental Strain rpsL 16S rRNA mutation Mutagenesis Reference 
      
SZ0380 ∆rrnB rrnA+ --- wt wt --- [22] 
SZ0004 ∆rrnB rrnA+ --- K42R wt Spont. [12] 
∆rrnB rrnA(G1491A) SZ0380 wt G1491A Recomb. this study 
∆rrnB rrnA(G1491A) SZ0004 K42R G1491A Recomb. [12] 
∆rrnB rrnA(G1491C) SZ0380 wt G1491C Recomb. this study 
∆rrnB rrnA(G1491C) SZ0004 K42R G1491C Recomb. [12] 
∆rrnB rrnA(G1491U) SZ0380 wt G1491U Recomb. this study 
∆rrnB rrnA(G1491U) SZ0004 K42R G1491U Recomb. [12] 
∆rrnB rrnA(C1409G) SZ0380 wt C1409G Recomb. this study 
∆rrnB rrnA(C1409G) SZ0004 K42R C1409G Recomb. [12] 
∆rrnB rrnA(C1409U) SZ0380 wt C1409U Recomb. this study 
∆rrnB rrnA(C1409U) SZ0004 K42R C1409U Recomb. [12] 
∆rrnB rrnA(A1408G) SZ0380 wt A1408G Recomb. this study 
∆rrnB rrnA(A1408G) SZ0004 K42R A1408G Recomb. [12] 
      
 413 
414 
415 
416 
417 
418 
419 
420 
Spont., spontaneous point mutation; Recomb., mutagenesis by RecA-mediated gene conversion.  
 
 
 
 
Table S2. Plasmids used in this study 
 
Number Plasmid Marker 16S rRNA mutations Reference 
pH022 pGEM7-rrnB5’3’-sacB-aph Gm - this study 
PZ176 pMV361∆aph-hyg-1491A Hyg G1491A [12] 
PZ178 pMV361∆aph-hyg-1491C Hyg G1491C [12] 
PZ177 pMV361∆aph-hyg-1491U Hyg G1491U [12] 
PZ191 pMV361∆aph-hyg-1409G Hyg C1409G [12] 
PZ175 pMV361∆aph-hyg-1409U Hyg C1409U [12] 
pH128 pMV361∆aph-hyg-1408G Hyg A1408G [13] 
     
 421 
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424 
Hyg, hygromycin; Gm, gentamicin. 
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